



(86) Date de dépôt PCT/PCT Filing Date: 2009/09/03
 (87) Date publication PCT/PCT Publication Date: 2010/03/11
 (45) Date de délivrance/Issue Date: 2015/03/31
 (85) Entrée phase nationale/National Entry: 2011/01/10
 (86) N° demande PCT/PCT Application No.: US 2009/004976
 (87) N° publication PCT/PCT Publication No.: 2010/027473
 (30) Priorité/Priority: 2008/09/03 (US61/093,975)

(51) Cl.Int./Int.Cl. *A61K 39/108* (2006.01),
A61K 38/10 (2006.01), *A61P 1/12* (2006.01),
C07K 14/24 (2006.01)
 (72) Inventeur/Inventor:
 SAEED, MAHDI A., US
 (73) Propriétaire/Owner:
 BOARD OF TRUSTEES OF MICHIGAN STATE
 UNIVERSITY, US
 (74) Agent: SMART & BIGGAR

(54) Titre : ENTEROTOXINE THERMOSTABLE D'ESCHERICHIA COLI IMMUNOGENE
 (54) Title: IMMUNOGENIC ESCHERICHIA COLI HEAT STABLE ENTEROTOXIN

(57) **Abrégé/Abstract:**

The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 March 2010 (11.03.2010)

(10) International Publication Number
WO 2010/027473 A3

(51) International Patent Classification:

A61K 39/108 (2006.01) *A61P 1/12* (2006.01)
C07K 14/24 (2006.01) *A61K 38/10* (2006.01)

(21) International Application Number:

PCT/US2009/004976

(22) International Filing Date:

3 September 2009 (03.09.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/093,975 3 September 2008 (03.09.2008) US

(71) Applicant (for all designated States except US): **BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY** [US/US]; Office Of Intellectual Property, 3900 Collins Road, Suite 1044, Lansing, MI 48910 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SAEED, Mahdi, A.** [US/US]; 1985 Groton Way, East Lansing, MI 48823 (US).

(74) Agents: **CARROLL, Peter, G.** et al.; Medlen & Carroll, LLP, 101 Howard Street, Suite 350, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

1 July 2010

(54) Title: IMMUNOGENIC ESCHERICHIA COLI HEAT STABLE ENTEROTOXIN

(57) Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.



WO 2010/027473 A3

IMMUNOGENIC ESCHERICHIA COLI HEAT STABLE ENTEROTOXIN

5

FIELD OF THE INVENTION

The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.

15

BACKGROUND OF THE INVENTION

Diarrheal diseases are one of the major causes of human death worldwide. Strains of enterotoxigenic *Escherichia coli* (ETEC) that produce heat-stable enterotoxin (STa) are an important cause of diarrheal disease in humans and animals. They are responsible for a significant proportion of diarrheal cases among infants, travelers going from non-endemic to endemic areas and neonatal mammals. The development of effective strategies to reduce the incidence and severity of ETEC-caused diarrhea has been hampered by the lack of an effective vaccine or immunotherapeutic agents against this enteric pathogen. Thus, there is a need to develop vaccines and other pharmaceuticals for the treatment of diarrhea and diarrheal related diseases and disorders.

SUMMARY OF THE INVENTION

The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.

The present invention relates to methods and compositions of the enterotoxigenic *Escherichia coli* heat stable enterotoxin (STa) through its unique coupling to a modified protein carrier (such as a modified BSA or "MBSA") and its effective use to produce STa-specific neutralizing antibodies produced by animals immunized with the STa-conjugate (including but not limited to rabbits, cows, and egg laying chickens), for the treatment and prevention of diarrhea and diarrheal related diseases and disorders. In some embodiments, said composition further comprises at least one antibody or antibody fragment reactive with STa. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders by using the STa-MBSA conjugate as an immunizing vaccine of pregnant animals and women with the anticipation of the production of protective STa-specific antibody in the milk colostrums that will offer protection by passive immunization to the nursing newborn subject against diarrhea caused by the STa-producing *Escherichia coli*. In still further embodiments, the invention relates to the treatment of constipation and urinary retention in humans and animals using the STa-conjugate described under the disclosed methods and compositions. In additional embodiments, said vaccine is an injectable composition. In additional embodiments, said vaccine is a composition applied in patch form and the antigen is administered transdermally. In additional embodiments, said vaccine is used to prevent Traveler's diarrhea.

In some embodiments, the invention relates to a method for treating diarrhea or diarrheal related disease or disorder comprising: providing: a subject at risk for diarrhea or a diarrheal related disease or disorder, and a composition comprising a heat-stable enterotoxin from *Escherichia coli*, and administering said composition to said subject

such that said symptoms are reduced. In further embodiments, said diarrhea or diarrheal related disease or disorder is selected from the group consisting of secretory diarrhea, osmotic diarrhea, motility-related diarrhea, inflammatory diarrhea, dysentery, infectious diarrhea, malabsorption disorders, inflammatory bowel syndrome, ischemic bowel disease, bowel cancer, hormone-secreting tumor related disorders, bile-salt diarrhea, chronic ethanol ingestion and urinary disorder. In still further embodiments, said subject is a mammal.

In some embodiments, the invention relates to a method for the prevention of diarrhea or diarrheal related disease or disorder in an unborn mammal comprising: providing: a subject impregnated with said unborn mammal, a composition comprising a heat-stable enterotoxin from *Escherichia coli*, and administering said composition to said subject such that the risk of said unborn mammal contracting said diarrhea or diarrheal related disease or disorder are reduced. In still further embodiments, said diarrhea or diarrheal related disease or disorder is selected from the group consisting of secretory diarrhea, osmotic diarrhea, motility-related diarrhea, inflammatory diarrhea, dysentery, infectious diarrhea, malabsorption disorders, inflammatory bowel syndrome, ischemic bowel disease, bowel cancer, hormone-secreting tumor related disorders, bile-salt diarrhea, chronic ethanol ingestion and urinary disorder. In additional embodiments, said subject is a mammal. In additional embodiments, said subject is a human.

In some embodiments, the invention relates to a method for treating constipation comprising: providing: a subject exhibiting symptoms associated with constipation that are resistant to common laxatives, and a composition comprising a heat-stable enterotoxin from *Escherichia coli*, and administering said composition to said subject such that said symptoms are reduced. In further embodiments, said subject is a mammal.

In some embodiments, the invention relates to a vaccine comprising heat-stable enterotoxin protein from *Escherichia coli* comprising an amino terminus, a cross-linker comprising first and second ends, and a carrier protein, wherein said first end of said cross-linker is covalently attached to said amino terminus of said enterotoxin and said second end of said cross-linker is covalently attached to said carrier protein. In further embodiments, said carrier protein is bovine serum albumin. In still further embodiments, the ratio of enterotoxin molecules to one molecule of bovine serum albumin is between 1

and 35, preferably between 1 and 10, more preferably between 3 and 7 and even more preferably between 4 and 5. In further embodiments, said vaccine generates an antibody having a specific binding titer of at least 10^{-6} . In further embodiments, said vaccine generates an antibody that has a neutralization capacity of at least 3×10^4 STa mouse units/ml. In additional embodiments, said enterotoxin protein has a specific activity of at least 1.22×10^3 MU/mg, more preferably at least 8.70×10^3 MU/mg and even more preferably 885×10^4 MU/mg. In further embodiments, said enterotoxin protein has a specific activity of at least. In still further embodiments, said vaccine is synthesized in the presence of a solvent. In additional embodiments, said solvent is dimethylformamide (DMF).

In some embodiments, the invention relates to a method of producing a STa-neutralizing antibody in egg laying hens, comprising: a) immunizing said hens with said Sta antigen; and b) collecting eggs, said eggs containing antibody reactive with said antigen. In some embodiments, the invention further relates to a method of producing a STa-neutralizing antibody in egg laying hens, comprising: a) immunizing said hens with said Sta antigen; and b) collecting eggs, said eggs containing antibody reactive with said antigen., wherein said antibody is extracted from the egg yolk of said eggs. In some embodiments, the invention relates to the previously mentioned STa-neutralizing antibody.

In some embodiments, the invention relates to a method for the treatment or prevention of diarrhea or a diarrheal related disorder comprising: administering said STa-neutralizing antibody to a subject. In some embodiments, the invention further relates to a method of administering said antibody wherein said STa-neutralizing antibody is an enterically coated antibody. In some embodiments, the invention further relates to an enterically coated STa-neutralizing antibody. In additional embodiments, said STa-neutralizing antibody is an injectable composition. In additional embodiments, said STa-neutralizing antibody is used to prevent Traveler's diarrhea.

Various embodiments of the invention provide a vaccine comprising heat-stable enterotoxin protein from *Escherichia coli* comprising an amino terminus, a cross-linker comprising first and second ends, and a carrier protein, wherein said first end of said cross-linker is covalently attached to said amino terminus of said enterotoxin and said second end of said cross-linker is covalently attached to said carrier protein.

Various embodiments of the invention provide a vaccine comprising an immunogenic conjugate that comprises heat-stable enterotoxin (STa) protein from *Escherichia coli* comprising an amino terminus that is covalently attached to a carrier protein via a carrier protein succinylated group selected from the group consisting of a succinylated lysine group, and a succinylated N-terminal amino group, wherein the vaccine conjugation efficiency is at least 52% and/or the retained biological activity is 100%.

Various embodiments of the invention provide a vaccine comprising an immunogenic conjugate that consists of heat-stable enterotoxin (STa) protein from *Escherichia coli* that is covalently attached to a succinylated carrier protein, wherein the vaccine conjugation efficiency is at least 52% and/or the retained biological activity is 100%.

Various embodiments of the invention provide a method of producing an STa-neutralizing antibody in egg laying hens, comprising: a) immunizing said hens with an STa antigen; and b) collecting eggs, said eggs containing antibody reactive with said antigen.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures.

5 Figure 1 shows the structural determinants of *Escherichia coli* heat-stable enterotoxin A (STa) (SEQ ID NO: 5).

Figure 2 shows structural characteristics for particular amino acid sequences of *E. coli* heat-stable enterotoxin A (STa) (SEQ ID NO: 6). StaP, (SEQ ID NO: 7), refers to the porcine isolate of Sta, while StaH, (SEQ ID NO: 8), refers to the human isolate.

10 Figure 3 shows the domain structures of guanylyl cyclases.

Figure 4 shows one possible mechanism for the pathophysiology of *E. coli* diarrhea. It is not intended that the present invention be limited to any particular theory based upon said pathophysiology.

15 Figure 5 shows the agarose electrophoresis gel of the PCR product of one embodiment of the present invention. Lane 1: 1500 bp ladder (DNA marker); Lane 2: Clinical *E. coli* isolate tested with 127 bp primer; Lane 3: Control *E. coli* strain (K12) tested with 127 bp primer; Lane 4: Clinical *E. coli* isolate tested with 244 bp primer; Lane 5: Control *E. coli* strain (K12) tested with 244 bp. Row A: 1500 bp ladder band; Row B: 500 bp ladder band; Row C: 100 bp ladder band.

20 Figure 6 shows growth kinetic curves at various pH levels for ETEC on a 36 L batch ASM under different pH using a Bellco bioreactor.

Figure 7 shows a reverse-phase-high performance liquid chromatography elution profile of 60% HPLC-grade methanol-MCI gel-STa-rich fraction on a preparative C8 Vaydac separation column.

25 Figure 8 shows the elution profile of biologically active *E. coli* heat-stable enterotoxin peaks on analytic Aquapore reverse-phase C8 Perkin-Elmer separation column.

Figure 9 shows the matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectroscopy profile of *E. coli* heat-stable enterotoxin.

Figure 10 shows an illustration depicting the bovine serum albumin (BSA)-carrier protein-*E. coli* STa peptide conjugate.

5 Figure 11 shows one possible mechanism for the reaction of succinic anhydride with the amino terminal group of a protein.

Figure 12 shows a size exclusion chromatograph of a native and a succinylated BSA molecule.

10 Figure 13 shows a MALDI-TOF mass spectrograph of a succinylated BSA molecule.

Figure 14 shows a MALDI-TOF mass spectrograph of an *E. coli* enterotoxin peptide-succinylated BSA carrier conjugate.

Figure 15 shows a MALDI-TOF mass spectrograph of an *E. coli* enterotoxin peptide-hypersuccinylated BSA carrier conjugate.

15 Figure 16 shows a MALDI-TOF mass spectrograph calculation of the change in molecular weight and conjugation ratio of the *E. coli* heat-stable enterotoxin peptide-suBSA carrier conjugate.

Figure 17 shows the procedure for performing an antibody capture ELISA assay as disclosed herein.

20 Figure 18 shows *E. coli* STa-specific serum antibody neutralization bioassay: Group 1 (rabbits 1, 2 and 3). The straight horizontal line lies at 0.083 GW/RBW = Gut weight/remaining body weight ratio, signifying the cut off value for STa- positive SAM.

Figure 19 shows the neutralization capacity of *E. coli* STa-specific serum antibody. The points represent the mean of neutralization titers from sera of three rabbits.

25 Figure 20 shows an *E. coli* STa-specific serum antibody neutralization bioassay for all rabbits. Three rabbits showed STa neutralizing antibodies by 12 weeks, another 3 rabbits showed STa neutralizing antibodies by 17 weeks, and, 2 rabbits started to show

STa neutralizing antibodies by 20 weeks post-immunization. GW= Gut weight; RBW= Remaining body weight.

Figure 21 shows an *E. coli* STa-binding ELISA optimization screening serum dilution assay for optimal *E. coli* STa-STa antibody interaction.

5 Figure 22 shows an *E. coli* STa-specific serum antibody: 10^{-4} serum dilution assay of group 1 rabbits.

Figure 23 shows an *E. coli* STa-specific serum antibody: 10^{-4} serum dilution assay of group 2 rabbits.

10 Figure 24 shows an *E. coli* STa-specific serum antibody: 10^{-4} serum dilution assay of group 3 rabbits.

Figure 25 shows the mean O.D. value of group 1 rabbits after 20 weeks (post-immunization) at various serum dilutions.

Figure 26 shows the mean O.D. value of group 2 rabbits after 20 weeks (post-immunization) at various serum dilutions.

15 Figure 27 shows the mean O.D. value of group 3 rabbits after 20 weeks (post-immunization) at various serum dilutions.

Figure 28 shows an end-titer of *E. coli* STa-specific serum antibody: 24 weeks (post-immunization) from eight rabbits.

20 Figure 29 shows an *E. coli* STa-specific serum antibody end titer. The mean O.D. values of group 1, 2 and 3 rabbits after 24 weeks (post-immunization) at various serum dilutions are shown.

Figure 30 shows a time-course evaluation of the avidity of *E. coli* STa-specific serum antibody using an ammonium thiocyanate dose response.

25 Figure 31 shows a 5 M thiocyanate elution profile of *E. coli* STa-STa serum antibody complex. The mean O.D. of treated serum from rabbit groups 1, 2 and 3 is shown.

Figure 32 shows an avidity index of *E. coli* STa-specific serum antibody from group 1, 2 and 3 rabbits using the avidity ELISA procedure disclosed herein.

Figure 33 shows standardization and optimization of the process of egg yolk antibodies extraction and purification.

Figure 34 shows Size Exclusion Chromatography (SEC) of extracted IgY vs standard chromatogram of SEC molecular weight standards.

5 Figure 35 shows Dose Response Competitive ELISA to establish specificity of the purified IgY from hens before immunization as a baseline.

Figure 36 shows Kinetics of egg yolk-derived STa-neutralizing antibody. Data shows the mean and standard deviation from yolk extract of 6 birds followed over 30 week period after primary immunization followed by boosters. Horizontal red line
10 indicates the cut off for effective STa-neutralization is a gut wt/remaining body wt ratio of 0.083 (Y axis).

Figure 37 shows Kinetic of immune response and levels of STa-neutralization measured by suckling mouse assay (Y axis) in 24 hens immunized with the STa vaccine and sampled over 30 weeks period.

15 Table I shows several properties used to distinguish *E. coli* heat-stable enterotoxin A (STa) and heat-stable enterotoxin B (STb).

Table II shows amino acid quantity and sequence properties associated with various STa toxins (SEQ ID NOs: 9-19).

Table III shows the PCR primers used to detect the STa gene as described herein
20 (SEQ ID NOs: 1-4).

Table IV shows the PCR running conditions for the detection of the STa gene as described herein.

Table V shows details of the PCR reaction for the detection of the STa gene as described herein.

25 Table VI shows the composition of the optimal minimal media for the production of STa (in g/L).

Table VII shows a summary of the purification procedures disclosed herein for *E. coli* STa per growth batch. MU = Mouse Unit = minimal amount of toxin producing

intestinal weight to remaining body weight ratio ≥ 0.085 . **Sp Ac** = Specific activity = total mouse unit/protein concentration **MED** = Minimal effective dose = protein concentration per mg/total mouse unit per million. **BAC** = Batch absorption chromatography. **Purification fold** = specific activity of STa from each step/ specific activity of STa in the cell free filtrate. Protein assay was done by Lowery method
5 (Lowery, 1951) using a Perkin Elmer spectrophotometer.

Table VIII shows the results of the disclosed conjugation experiments, providing for the evaluation of the four disclosed conjugation protocols. DCC = *N,N*-dicyclohexyl carbodiimide; EDAC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
10 DMF = dimethylformamide; PB = Phosphate buffer. MES = 2-(*N*-morpholino)ethanesulfonic acid buffer; suBSA = succinylated BSA. HS = hypersuccinylated BSA; *P-NP* = *p*-nitrophenol.

Table IX shows the amino acid compositional analysis of *E. coli* STa-su BSA carrier conjugate replicates.

15 Table X shows the approximate contribution of STa molecules to one molecule of modified BSA and a calculation of the conjugation ratio.

Table XI shows an *E. coli* STa-specific serum antibody end titer. The mean OD \pm SD value of group 1, 2 and 3 rabbits after 24-week post-immunization at various serum dilutions is shown.

20 Table XII shows Summary of STa-ELISA binding and neutralization end titers of rabbit sera immunized with STa-suBSA conjugate after the primary immunization and during the boosting intervals. The data were generated by STa-binding ELISA and STa-neutralization methods using a suckling mouse assay.

25 Table XIII shows a summary of the development of STa antibody avidity after multiple boosters with the STa conjugate using 5 M ammonium thiocyanate ELISA dissociation assay.

Table XIV shows Neutralization capacity of sera from animals immunized with several STa immunogens and the end titers of the STa-neutralizing antibodies.

Table XV show the neutralization capacity of STa-specific IgY extracted from egg yolk samples of 24 hens immunized with the STa vaccine. STa neutralization scores based on suckling mouse assay. A ratio of gut weight: remaining body weight of < 0.085 signifies a positive STa - neutralization. Avidity index (%) for each sample is listed in the last column.

DEFINITIONS

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

As used herein, “diarrhea” and “diarrheal related diseases and disorders” refer to any condition that results in frequent loose or liquid bowel movements. While not limiting the scope of the present invention, diarrhea and diarrheal conditions may be incurred due to gastroenteritis, an inflammation of the gastrointestinal tract. Diarrhea and diarrheal related diseases and disorders include but are in no way limited to secretory diarrhea, osmotic diarrhea, motility-related diarrhea, inflammatory diarrhea, dysentery, infectious diarrhea, malabsorption disorders, inflammatory bowel syndrome, ischemic bowel disease, bowel cancer, hormone-secreting tumor related disorders, bile-salt diarrhea and chronic ethanol ingestion.

As used herein, “Sta” refers to the amino acid sequences of *E. coli* heat-stable enterotoxin A. StaP refers to the porcine isolate of Sta, while StaH refers to the human isolate.

A carrier protein is an antigenic polypeptide entity that induces the formation of antibodies directed against an antigen conjugated to it, by the immune system of an organism into which the carrier-antigen conjugate is introduced. Although many short

epitopes are protective, they are poorly immunogenic. By conjugating an immunogenic carrier protein to a molecule that is poorly immunogenic, it is possible to confer higher immunogenicity. Such conjugate molecules stimulate the generation of an immune response and thus have been effectively used in vaccines that protect against pathogens
5 for which protective immunity could not otherwise be generated.

Hence, highly immunogenic proteins (such as tetanus toxoid) have historically been used as carriers in order to induce a Th cell response that provides help to B cells for the production of antibodies directed against non-immunogenic epitopes. However, overall effectiveness has not been generally achieved with this approach, since the
10 antibody response to a hapten (the epitope) coupled to a carrier protein can be inhibited when the recipient host has been previously immunised with the unmodified carrier protein. This phenomenon is termed epitope-specific suppression and has now been studied in a variety of hapten- carrier systems.

Useful antibodies or antibody fragments may be monoclonal or polyclonal.
15 Antibodies may be made in birds. Mammalian antibodies are preferably of the class IgG, but may also be IgM, IgA, IgD or IgE. Fragments of an antibody, such as an Fab, Fv, CDR, etc. are contemplated.

Several immunologic carriers, some protein carriers, are known in the art, including, but not limited to, keyhole limpet hemocyanin (KLH), bovine serum albumin
20 (BSA), ovalbumin (OVA), beta-galactosidase (B-GAL), penicillinase, poly-DL-alanyl-poly-L-lysine, and poly-L-lysine.

In one embodiment, the present invention contemplates modified carrier protein, such as modified BSA (MBSA). In one embodiment, the modified BSA is chemically modified, e.g. succinylated which results in "suBSA" succinylated BSA. In suBSA,
25 Bovine serum albumin is modified with succinic anhydride so that lysine residues are acylated. The free amino groups are modified. The degree of modification can vary based upon how many amino groups are acylated. Succinic anhydride (SA) reacts rapidly with the E-amino groups of lysines and the α -amino groups of the *N*-termini of proteins at pH 7-9, forming an amide bond by replacing the amino group with a carboxyl. Thus,
30 introducing a succinic anhydride moiety on BSA will afford a protein derivative with

more carboxyl groups and hence increase the possibility to link STa from its amino terminal and preserve its antigenic determinants associated with the carboxyl terminal of the molecule. Hyper-Succinylated Bovine Serum Albumin (HS-BSA) is produced via an extensive modification of the BSA by introducing a large number of succinyl moieties
5 [COO-] on the carrier protein could be achieved in a hyper-succinylation reaction.

As used herein, the terms "prevent" and "preventing" include the prevention of the recurrence, spread or onset of a disease or disorder. It is not intended that the present invention be limited to complete prevention. In some embodiments, the onset is delayed, or the severity of the disease or disorder is reduced. For example, in terms of severity, the
10 number of bowel movements (and the consequent amount of water lost) is, in one embodiment, reduced. Alternatively, other symptoms, included but in no way limited to abdominal pain, fever, weight loss, dehydration, excessive perspiration, gastroenteritis, bloody stool and malabsorption of food may be reduced.

As used herein, the terms "treat" and "treating" are not limited to the case where
15 the subject (e.g. patient) is cured and the disease is eradicated. Rather, the present invention also contemplates treatment that merely reduces symptoms, improves (to some degree) and/or delays disease progression. It is not intended that the present invention be limited to instances wherein a disease or affliction is cured. It is sufficient that symptoms are reduced.

20 "Subject" refers to any mammal, preferably a human patient, livestock, or domestic pet. A "subject at risk for diarrhea or diarrheal related disease or disorder" means a subject at risk for exposure to enterotoxigenic *Escherichia coli* (ETEC) and/or a subject residing or traveling in an area or areas afflicted by ETEC.

In a specific embodiment, the term "pharmaceutically acceptable" means
25 approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient or vehicle with which the active compound is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or
30 synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The

pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. When administered to a subject, the pharmaceutically acceptable vehicles are preferably sterile. Water can be the vehicle
5 when the active compound is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,
10 propylene glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

An enteric coating is a barrier applied to oral medication that controls the location in the digestive system where it is absorbed. "Enteric" refers to the small intestine, therefore enteric coatings prevent release of medication before it reaches the small
15 intestine. Most enteric coatings work by presenting a surface that is stable at the highly acidic pH found in the stomach, but breaks down rapidly at a less acidic (relatively more basic) pH. For example, they will not dissolve in the acidic juices of the stomach (pH ~3), but they will in the higher pH (above pH 5.5) environment present in the small intestine. Materials used for enteric coatings include fatty acids, waxes, and shellac as
20 well as plastics.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and
25 humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.

In some embodiments, the invention relates to the treatment of diarrheal disease
30 and symptoms in mammalian subjects. Enterotoxigenic *Escherichia coli* (ETEC) is a

major enteropathogen that causes potentially fatal diarrhea in both human and animal neonates as disclosed in Moon *et al.* (1993) *Vaccine* 11, 213-220 and Tacket *et al.* (1994) *Vaccine* 12, 1270-1274. It is also

5 responsible for a large proportion of diarrheal disease among adult travelers as disclosed in Tacket *et al.* (1994) *Vaccine* 12, 1270-1274. Therefore, strategies to reduce the incidence and severity of ETEC diarrhea have been considered an important public health priority as disclosed in Tacket *et al.* (1994) *Vaccine* 12, 1270-1274. A large proportion of ETEC diarrhea is caused by heat-stable enterotoxin (STa), a small peptide (2kD), which is an important virulence determinant in enterotoxin-mediated diseases as disclosed in
10 Sears *et al.* (1996) *Microbiology Reviews* 60, 167-215 and Giannella *et al.* (2003) *Transactions of the American Clinical and Climatological Association* 114, 67-85.

Upon infection, the STa-producing ETEC adheres to the epithelium of the small intestine via one or more colonization factor antigens or pili surface proteins. Once established, ETEC elaborates heat-stable
15 enterotoxin (STa), which acts on a specific intestinal membrane bound receptor, guanylyl cyclase C, initiating a cascade of altered metabolic pathways. This may result in secretory diarrhea among affected adults and fatal dehydration in infants.

Methods for the treatment and control of ETEC diarrhea are still a matter of debate among veterinarians, livestock producers and other animal experts. The use of
20 sub-therapeutic doses of antibiotics may help protect animals from some, but not all, diarrhea inducing bacterial strains. Moreover, the use of antimicrobials at sub-therapeutic levels has been linked to emerging antibiotic resistance among several bacterial species, including ETEC strains. While there are several reagents that are in use against ETEC derived diarrheal diseases in animals, most of these reagents are based on surface
25 structures of the ETE strains. Furthermore, the development of a broad-spectrum vaccine against ETEC remains elusive as disclosed in Walker *et al.* (2007) *Vaccine* 25, 2545-2566, incorporated herein by reference. While not limiting the current invention to any particular theory, it is believed that two major technical problems contribute to this deficiency. The first involves the production of immunogenic preparations of antigens
30 with the ability to confer broad-spectrum protection against ETEC infections. The second is the challenge of achieving effective mucosal immunization as disclosed in Walker *et*

al. (2007) *Vaccine* 25, 2545-2566, due to the multiplicity, antigenic diversity, and high prevalence of unidentifiable forms of specific colonization antigens responsible for mucosal adherence as disclosed in Thomas *et al.* (1982) *Medical Microbiology and Immunology* 171, 85-90.

5 is an urgent need to define a new common antigenic determinant that could provide broad protection against ETEC-STa-induced diarrhea. Saeed *et al.* (1985) *Microbiology and Therapy* 15, 221-229, reported that calf scour could be experimentally induced by a highly purified STa preparation, supporting the notion that ETEC STa is the immediate mediator of diarrhea in calves. Additionally, several studies
10 have demonstrated a significant correlation between STa-producing ETEC strains and diarrhea, and that 75% of ETEC strains produce STa either alone or in combination with heat-labile enterotoxin (LT) as provided for in Wolf (1997) *Clinical Microbiology Reviews* 10, 569-584. Thus, the inclusion of STa in colonization factor-based ETEC vaccines or the production of neutralizing STa antibodies
15 would potentially offer immune protection against ETEC-caused diarrhea.

However, this approach has been a challenge, partly because of the haptenic nature of STa (molecular weight of less than 2 kDa), which fails to elicit an antibody response as provided for in Boedeker (2005) *Current Opinions in Gastroenterology* 21, 15-19.

20 Additionally, the correlation between STa toxicity and antigenicity as disclosed in Takeda *et al.* (1993) *Infection and Immunity* 61, 289-294, hampers the ability to produce a safe STa/CFAs vaccine. However, it was hypothesized that the poor immunogenicity associated with the STa molecule could be improved by conjugation of the STa to a suitable macromolecule (carrier protein) as provided for in Pauillac *et al.* (1998) *Journal of Immunological Methods* 220, 105-114.
25

While not limiting the scope of the present invention, it is believed that antibody-based therapy (passive immunization) targeting the STa antigen could be used to reduce the impact of ETEC-STa induced diarrhea and avoid the safety issue associated with active immunization with CFA/Itoxin based-vaccine. Attempts to conjugate the STa to a carrier
30 protein have been disclosed in Clements (1990) *Infection and Immunity* 58, 1159-1166.

However, previous disclosures were unclear regarding the efficiency and characteristics of these conjugates.

In preferred embodiments, the invention relates to a modified enterotoxin conjugate. The potential of using the vaccine to produce egg yolk-derived STa-antibody since it induced a very high titer of specific and neutralizing antibodies in immunized rabbits and recently in immunized egg laying hens at our laboratory (our recent data demonstrated that the STa conjugate induced a neutralizing antibody that we were able to extract from the yolk of eggs laid by the immunized hens).

In some embodiments, the invention relates to immunotherapy using antibodies raised against the conjugated STa toxin. In some embodiments, the invention relates to the using the STa-neutralizing antibodies as a prophylactic to prevent diarrhea. In some embodiments, the invention relates to the using the STa-neutralizing antibodies (or antibody fragments) to relieve symptoms of traveler's diarrhea and speed recovery. In some embodiments, the invention relates to the using the STa-neutralizing antibodies in a pill, powder, or injectible form.

In some embodiments, the invention relates to the using the STa-neutralizing antibodies as animal milk replacers additives and as additive to infant formula milk.

The potential of using this vaccine to immunize pregnant animals (cattle, sheep, goats, sows, horses and all animals that may be affected by the STa-producing *E. coli*). Immunization will produce STa-antibody enriched colostrums that will offer protection to newborn animals against diarrheal disease caused by STa-producing *E. coli*.

The potential of using the vaccine, and any of its modifications that may include changing the carrier to better suit human subjects, to immunize pregnant women to induce STa-antibody enriched colostrums that will protect the newborn infants against the STa-induced diarrheal disease (using subcutaneous, intramuscular, oral, skin patches, and inhalation routes).

The potential of using the vaccine to produce commercial amounts of STa-specific antibodies by immunizing dairy cattle and egg laying hens to extract and purify the antibodies from colostrums and eggs respectively using established technologies. These antibodies can be appropriately packaged and offered to humans (infants, children,

adult travelers, and troops) and newborn animals (calves, piglets, sheep, and goats and other animals at risk of STa-induced diarrhea).

The potential of using the vaccine to treat human clinical disease such as: chronic constipation, urinary retention (after general anesthesia), colon polyps and cancer, alleviate high blood pressure (hypertension) due to congestive heart failure and renal dysfunction, systemic dysfunctions including all enteric, glandular, neurological diseases that are mediated by disturbances in intracellular and particulate forms of cyclic GMP.

In some embodiments the invention relates to compositions of the enterotoxigenic *Escherichia coli* heat stable enterotoxin (STa) through its unique coupling to a modified protein carrier (such as a modified BSA or "MBSA") as a laxative. In some embodiments the invention relates to compositions of the enterotoxigenic *Escherichia coli* heat stable enterotoxin (STa) through its unique coupling to a modified protein carrier (such as a modified BSA or "MBSA") as a laxative prior to colonoscopy or intestinal surgery. Conjugated STa could replace current magnesium laxatives, which are unpleasant to drink and must be taken well in advance of the procedure.

In some embodiments the invention relates to compositions of the enterotoxigenic *Escherichia coli* heat stable enterotoxin (STa) through its unique coupling to a modified protein carrier (such as a modified BSA or "MBSA") as a treatment of post-anaesthesia urine retention in humans, which would lower the need for post-operative catheterization.

In some embodiments the invention relates to compositions of the enterotoxigenic *Escherichia coli* heat stable enterotoxin (STa) through its unique coupling to a modified protein carrier (such as a modified BSA or "MBSA") in a Detection kits: using the antibodies to STa to make a detection kit for enteropathogenic *E. coli*.

25 PHARMACEUTICAL FORMULATIONS

The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form

suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see e.g., U.S. Pat. No. 5,698,155).

In a preferred embodiment, the active compound and optionally another therapeutic or prophylactic agent are formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous administration to human beings. Typically, the active compounds for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the active compound is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the active compound is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for an orally administered of the active compound. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate can also be used. Oral

compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. Such vehicles are preferably of pharmaceutical grade.

Further, the effect of the active compound can be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the active compound can be prepared and incorporated in a tablet or capsule. The technique can be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules can be coated with a film that resists dissolution for a predictable period of time. Even the parenteral preparations can be made long acting, by dissolving or suspending the compound in oily or emulsified vehicles, which allow it to disperse only slowly in the serum.

Compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable vehicles or excipients.

Thus, the compound and optionally another therapeutic or prophylactic agent and their physiologically acceptable salts and solvates can be formulated into pharmaceutical compositions for administration by inhalation or insufflation (either through the mouth or the nose) or oral, parenteral or mucosal (such as buccal, vaginal, rectal, sublingual) administration. In some embodiments, the administration is optical (e.g. eyes drops applied directly to the eye). In one embodiment, local or systemic parenteral administration is used.

For oral administration, the compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with

water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration can be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compositions for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compositions can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

In addition to the formulations described previously, the compositions can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular

injection. Thus, for example, the pharmaceutical compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

5 The compositions can, if desired, be presented in a pack or dispenser device that can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.

10 In certain preferred embodiments, the pack or dispenser contains one or more unit dosage forms containing no more than the recommended dosage formulation as determined in the Physician's Desk Reference (62nd ed. 2008, herein incorporated by reference in its entirety).

15 Methods of administering the active compound and optionally another therapeutic or prophylactic agent include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal, rectal, vaginal, sublingual, buccal or oral routes). In a specific embodiment, the active compound and optionally another prophylactic or therapeutic agents are administered intramuscularly, intravenously, or subcutaneously. The active compound and optionally another prophylactic or therapeutic agent can also be
20 administered by infusion or bolus injection and can be administered together with other biologically active agents. Administration can be local or systemic. The active compound and optionally the prophylactic or therapeutic agent and their physiologically acceptable salts and solvates can also be administered by inhalation or insufflation (either through the mouth or the nose). In a preferred embodiment, local or systemic parenteral
25 administration is used.

30 In specific embodiments, it can be desirable to administer the active compound locally to the area in need of treatment. This can be achieved, for example, and not by way of limitation, by local infusion during surgery or topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-

porous, or gelatinous material, including membranes, such as silastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of an atherosclerotic plaque tissue.

5 Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the active compound can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

10 The amount of the active compound that is effective in the treatment or prevention of macular degeneration or angiogenesis can be determined by standard research techniques. For example, the dosage of the active compound which will be effective in the treatment or prevention of age-related macular degeneration can be determined by administering the active compound to an animal in a model such as, e.g., the animal models known to those skilled in the art. In addition, *in vitro* assays can optionally be employed to help identify optimal dosage ranges.

15 Selection of a particular effective dose can be determined (e.g., via clinical trials) by a skilled artisan based upon the consideration of several factors, which will be known to one skilled in the art. Such factors include the disease to be treated or prevented, the symptoms involved, the subject's body mass, the subject's immune status and other factors known by the skilled artisan.

20 The dose of the active compound to be administered to a subject, such as a human, is rather widely variable and can be subject to independent judgment. It is often practical to administer the daily dose of the active compound at various hours of the day. However, in any given case, the amount of the active compound administered will depend on such factors as the solubility of the active component, the formulation used, 25 subject condition (such as weight), and/or the route of administration.

PREFERRED EMBODIMENTS

In a preferred embodiment, BSA was modified by introducing succinic moieties. Extensive modification of the free amino groups was achieved with the addition of succinic anhydride as disclosed in Habeeb (1967) *Journal of Immunology* 99, 1264-1276.

5 The subsequent step in the design of STa-BSA conjugate was the cross-linking of STa to the modified BSA. In one embodiment, this reaction was initiated by incubation of the modified BSA with p-nitrophenol and DCC (i.e. a carbodiimide) for three hours to provide reactive ester groups that could easily attach the STa from its amino terminal, forming amide linkages. The use of DMF was shown to enhance the solubility of

10 reactants including peptides and carrier proteins as disclosed in Lateef (2007) *Journal of Biomolecular Techniques* 18, 173-176. We believe that the use of DMF as a solvent reagent may have facilitated the solubility of the hydrophobic STa molecules, solving a problem encountered with the other solvents and coupling media. The STa-conjugate was tested for its protein content and biological

15 activity. Based on the protein estimation, there was a conjugation efficiency of 52-64%. Moreover, this conjugate showed a higher biological activity than any activity reported in the previous STa-conjugates

EXPERIMENTAL

The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

5 In the experimental disclosure which follows, the following abbreviations apply:
 N (normal); M (molar); mM (millimolar); μ M (micromolar); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); pmol (picomoles); g (grams); mg (milligrams); μ g (micrograms); ng (nanograms); l or L (liters); ml (milliliters); μ l (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers);
 10 C (degrees Centigrade); miR or miRNA (microRNA); BSA (bovine serum albumin); PCR (polymerase chain reaction); bp (base pair).

EXAMPLE I.**15 MATERIALS AND METHODS****ANIMALS**

Swiss Webster Mice: A group of 20 Swiss-Webster (fifteen females and five males) was used to establish a colony as a source of suckling mice for STa bioassay. Exhausted females and males were continuously replaced with younger animals to ensure
 20 production efficiency of infant mice litters by the colony.

REAGENTS

All reagents were obtained from commercial sources and were of analytical grade. Mobile phases used for purification of STa include HPLC-grade methanol, trifluoroacetic
 25 acid, as well as the other chemical ingredients listed under this section.

Verifying the ETEC K99+ Strain: The PCR protocol disclosed in Olsvick *et al.* (1993) *Diagnostic Molecular Biology*, American Society for Microbiology (Washington, D.C.) and Salvadori *et al.* (2003) *Journal of Microbiology* 34, 230-235,

was used to detect the STa gene and verify the strain as
 30 STa-producing *E. coli*.

Bacterial Strains: An ETEC strain was isolated from a clinically diarrheic neonatal calf and was provided by A. M. Saeed (Molecular Epidemiology Laboratory, National Food Safety Toxicology Center (NFST), Michigan State University (MSU), East Lansing, MI). A control strain (K-12 *E. coli*) was kindly obtained from the Bacterial Evolution Laboratory, NFST, MSU, East Lansing- MI.

DNA Extraction (Template) by boiling lysis: ETEC and K-12 strains were grown on Trypticase Soy Agar slants overnight at 37°C. A uniform bacterial colony from both strains was taken and suspended in 1 ml sterile Milli Qwater and boiled for 10 minutes, then left in ice for 5 minutes, followed by centrifugation at 13,000 rpm for 4 minutes. The supernatant was taken and kept at -20°C until use as provided for in Holmes *et al.* (1981) *Analytical Biochemistry* 114, 193-197.

Primer selection and preparation: Two different sizes of STa primer, 244 bp and 127 bp (Table III), were obtained from Integrated DNA Technology Inc. (Coralville, IA). The STa primers for 244 base pair product (SEQ ID NO: 1) 5'- TCC GTG AAA CAA CAT GAC GG-3' and (SEQ ID NO: 2) 5'- ATA ACA TCC AGC ACA GGC AG-3'. The STI primers for 127 base pair product (SEQ ID NO: 3) 5'- TTA ATA GCA CCC GGT ACA AGC AGG-3' and (SEQ ID NO: 4) 5'- CTT GAC TCT TCA AAA GAG AAA ATT-3'. Both primers were prepared according to the manufacturer's instructions.

PCR program: PCR running conditions for detection of the STa gene is presented in Table IV using PCT-100 Programmable Thermal Controller (MJ Research, Inc).

PCR reaction: The PCR reaction was performed as described in Table V using a Fisher exACTGene Complete PCR kit.

Agarose Gel Electrophoresis Analysis of PCR Products: The analysis of the PCR products was performed in 2% agarose gel electrophoresis using the Horizontal Gel Electrophoresis System, Life Technology (Cat # 11068-012). Briefly, two percent of agarose was prepared (1.5 gm/75 ml 1xTAE electrophoretic sequence grade) and ethidium bromide was added at a concentration of 3 µl/50 ml. The reagent was poured into the electrophoretic chamber and filled with 1xTAE. Five volumes of PCR product were mixed with 1 volume of gel loading buffer and loaded into the wells along with a 1.5 kb ladder. The agarose gel was left to run at the appropriate voltage (100-160 volts) for 30-45 minutes and examined via UV irradiation.

PURIFICATION AND CHARACTERIZATION OF *E. COLI* STa

STa was purified as disclosed in Staples *et al.* (1980) *Journal of Biology Chemistry* 155, 4716-4721, Saeed *et al.* (1983) *Infection and Immunity* 40, 701-710 and
5 Saeed *et al.* (1985) *Analytical Biochemistry* 151, 431-437.

Seed culture and frozen stock of ETEC preparation. Casamino acid-yeast extract-salts (CAYE) seed culture was used for optimal growth of the ETEC strain as disclosed in Giannella (1976) *Transactions of the American Clinical and Climatological Association* 114, 67-85. The ETEC strain was grown on 500 ml of CAYE, incubated at
10 39°C for 24 hours on a rotary shaker at 120 rpm, mixed with glycerol at a final concentration of 15%, then aliquoted into 10 ml samples and frozen at -80°C (frozen stock).

Batch Medium (Asparagine Salt Medium) and Growth Conditions. Medium was
15 prepared as described in Staples *et al.* (1980) *Journal of Biology Chemistry* 155, 4716-4721. The disclosed media was found to offer several advantages, including high level of STa production along with minimal contaminating proteins that facilitated the STa-purification process. Each batch consisted of 30 liters of culture-innoculated ASM grown in a 36L omni vessel under different pH conditions (7.4, 8 and 8.6) using a Bellco
20 bioreactor (Bellco Glass Inc., Vineland NJ). Preculture was prepared by inoculating 10 ml of frozen stock of ETEC into 1L of CAYE broth and was incubated at 39°C for 24 hours on a rotary shaker at 120 rpm. The preculture medium was then transferred into 30 liters of batch medium and kept at 39°C under continuous agitation at 120 rpm, aeration and oxygenation were at a rate of 5 Umin and 600 ml/min, respectively, through a
25 sintered metal dispersion ring. Foam, speed of agitation, temperature and O₂ pressure was controlled using Bellco control modules. Samples were taken every two hours to determine the growth kinetics under various pH levels.

Preparation of cell free filtrate. After 24 hours of incubation, the growth medium was immediately filtered by tangential flow filtration through a 0.2 micron cassette in
30 Millipore Pellicon System (Millipore Corp, Bedford, MA). Cell free filtrate was kept on ice throughout the time of filtration to minimize bacterial growth and enzymatic activity.

Samples from the cell-free filtrate were collected for determination of total protein and STa content using suckling mouse assay.

Amberlite XAD-2 Batch Adsorption Chromatograph. Cell-free filtrate was desalted and the hydrophobic STa was concentrated using Amberlite XAD-2 batch
5 adsorption chromatography. Amberlite XAD-2 resin was first washed extensively with purified water to remove any preservative and powdery contaminants. Then 500 grams were suspended into 15 L of cell free filtrate in a 20 L carboy and kept overnight at 4°C under gentle stirring. Resin was poured from the carboy into a 40 cm long glass column and washed with 5 L of Milli Qwater. The contaminants loosely bound to the resin were
10 eluted with 1L of 1% acetic acid in 20% methanol/water (v/v). A stepwise elution system was applied to elute the STa ~tarting with 1 L of 1% acetic acid in 80% methanol/water (v/v) followed by 1 L of 1% acetic acid in 99% methanol/water (v/v) and finally 1 L of 50% acetone/water (v/v). The last three fractions were pooled and concentrated by flash evaporation and freeze-drying. The resin was degassed for 5 minutes after each solvent
15 was added to drain completely before further addition of solvent. Samples were collected for determination of the total protein and testing for STa biological activity in suckling mouse.

Acetone Fractionation. Lyophilized crude STa was dissolved in 20 ml of 25% of acetic acid. Acetone was added to bring the final volume to 100-150 ml. After standing
20 hour at 4°C, the sample was centrifuged at 10,000g for 30 minutes at 4°C. The supernatant fraction was evaporated to remove the acetone and was then freeze-dried. Samples were collected for protein determination and STa biological activity.

Reversed-Phase Batch Adsorption Chromatography (MCI-gel). An intermediate purification step was applied to the acetone STa-rich fraction to achieve a further level of
25 STa purity. The lyophilized crude STa was solubilized in 100 ml of 0.1% of 20% HPLC-grade methanol. To this solution, 100 grams of Reverse- Phase Methacrylate Adsorbent Polymer Resin (340°A, 30 μm; Mitsubishi Chemical Corporation, Catalog # CHP2MGY-01L) was slowly added under gentle mixing and the slurry was kept at 4°C for 2 hours under gentle shaking. The slurry was poured into a 10-mm (inner diameter) x 25-cm-long
30 glass column. The column was washed with 300 ml 0.1% TFA/H₂O (v/v). Stepwise elution of the proteins was performed with 100 ml of 0.1% TFA of 20, 40, 60, 80 and

100% MeOH (v/v). Fractions were collected separately from each elution step. The methanol and TFA were evaporated and the residues were tested for protein and STa biological activity.

Preparative Reverse-Phase High Performance Liquid Chromatography (RP-HPLC). RP-HPLC was performed on Waters Associate Liquid Chromatography System equipped with multi-solvent delivery pumps, an automated gradient programmer 600S controller, Model 486 tunable absorbance detector using 7 μm , 300 \AA , 25 cm x 10 mm inner diameter Vydac C8 preparative columns (Sorbent Technologies, Inc., Atlanta, GA). Samples from RP-methacrylate adsorbent polymer resin were applied on an RP-C8 column and STa was eluted by gradient system with 0.1% TFA in water as solvent A and 0.1% TFA in 80% methanol as solvent B (0-30% for 5 min and 30-80% for 80 min). The UV absorbing peaks were detected at 214 nm. Peaks were collected separately and the methanol was evaporated then freeze-dried. The resulting freeze-dried substance was reconstituted into physiologically balanced saline and evaluated for protein content and STa biological activity.

STa Assessment for Biological Activity. Detecting and quantifying STa biological activity was done using a reference standard *in vivo* model test, suckling mouse assay, according to Dean *et al.* (1972) *The Journal of Infectious Diseases* 125, 407-411 and Giannella (1976) *Infection and Immunity* 14, 95-99, both of which are hereby incorporated by reference. Newborn Swiss Albino suckling mice (2-3 days old) were randomly divided into groups (three each). Samples from RP-HPLC were serially diluted 1/100; 1/10,000 & 100,000 and 10 μl of 0.2% Evans blue (w/v) was added per ml. Each suckling mouse was inoculated orally by 100- μl sample using a 1 ml syringe and a 20- μm diameter polyethylene tube. Each sample dilution was tested in triplicate. After 2-hour incubation at room temperature, the mice were euthanized by carbon dioxide in a CO₂ chamber and the intestine, not including the stomach, was removed from each newborn mouse and weighed. The ratios of intestinal weight to remaining body weight of the three mice were determined. Animals with no dye in the intestine or with dye within the peritoneal cavity at autopsy were discarded. One unit of ST activity (one mouse unit) is defined as the minimal amount of toxin that produces an intestinal weight/carcass ratio of greater than 0.083.

Criteria for homogeneity of purified STa. Homogeneity of the purified STa from preparative runs was validated by analytic aquapore RP-300A Perkin Elmer C8 column. Additionally, the exact molecular weight of STa was determined by matrix-assisted laser desorption ionization-time of flight mass spectroscopy (MALDI-TOF/MS). The purified
5 STa was then submitted for amino acid sequencing.

RESULTS AND DISCUSSION

Detection of STa gene. PCR amplification verified that the tested strain carried the gene encoding for STa after analyzing the product on gel electrophoresis. Two amplicon
10 bands of 127 bp and 244 bp were detected under UV light for the tested strain, which were not apparent for the control strain (*E. coli* K-12) (Figure 5).

Culture analysis. Growth kinetics experiments were conducted on 30 L batch cultures under various pH values (7.4, 8 and 8.5). Samples were taken every two hours and the growth pattern was determined by counting the total cell count (CFU/ml) using a
15 robotic spiral plate and computer linked camera (Q counter). As Figure 6 indicates, tested ETEC growth was maximal in medium in which the initial pH was adjusted to 7.4. This level of growth was associated with higher level of crude STa as verified by the suckling mouse assay.

Purification and Characterization of E. coli STa. Table VII shows the summary
20 of the purification scheme of SrTa for the ETEC *E. coli* in 30 L batch culture.

Amberlite XAD-2 Batch Adsorption Chromatography. This step yields a high specific activity of the crude STa (8.70×10^3 MU/mg protein) compared with the STa specific activity in the cell free filtrate (1.22×10^3 MU/mg protein).

Acetone fractionation. Acetone fractionation resulted in further purification of the
25 STa by removing additional amount of non-STa protein that was precipitated in acetone. Samples were taken for protein determination and STa biological activity. Specific activity of STa increased to 88.7×10^3 MU/mg protein.

Reversed Phase-Batch Adsorption Chromatography (MCI-gel). Specific activity
30 of the STa at this step of purification increased from 88.7×10^3 to 112×10^3 MU/mg protein. This step allowed for a larger sample load on preparative RP-HPLC. Up to 15

mg of the crude STa cleaned by this procedure could be used as a single load in RP-HPLC without overloading the column or losing the resolution. This has led to a considerable reduction in the number of HPLC runs needed to purify STa.

Preparative Reverse-Phase HPLC Chromatography (RP-HPLC). Sixty percent methanol MCI-gel STa-rich fractions were loaded on a preparative C8 column for further purification. Figure 7 and Figure 8 describe the elution profiles of STa. Elution with an increasing methanol gradient resulted in number of absorbance peaks at 214 nm (Figure 7), the last of which was found to contain enterotoxin activity. The enterotoxin peak began to elute at approximately 55-60% methanol after 35 minutes retention time. This peak was collected and after methanol evaporation, was freeze-dried. It was then reconstituted into physiological saline and tested for STa biological activity and protein concentration. Further improvement in the STa specific activity (885×10^4 MU/mg) was achieved in this step. The biological activity was demonstrated to be 0.113 ng per one mouse unit of STa minimal effective dose (MED) in 2-3 day-old inoculated Swiss Webster suckling mice.

Criteria for Homogeneity of Purified STa.

- *Analytic C8 Column:* Pooled peaks from several preparative RP-HPLC runs were tested on an analytic aquapore RP-300A Perkin Elmer C8 column to demonstrate a single symmetrical peak (Figure 8).

- *Mr-Value Determination Using Matrix Assisted Laser Desorption Ionization Time of Flight/Mass Spectroscopy:* A lyophilized HPLC-purified sample was analyzed by MALDI-TOF/MS to determine the molecular weight and the result is shown in Figure 9. The observed signal at 100% MS intensity with *m/z* = 1972.1 indicates that the M_r of the purified product is 1972.1 Da, which is compatible with the M_r (1969-1972) value calculated from amino acid composition of the STa, confirming the purity and identity of the purified product as the STa molecule. This was in agreement with the findings of Takao *et al.* (1983) *FEBS Lett.* 152, 1-5.

- *Amino Acid Sequence:* Further confirmation of the homogeneity and identity of the purified product was performed by determination of amino acid sequence. A

lyophilized HPLC-purified sample was submitted for amino acid sequence analysis and the results showed the 18 amino acid residues of the STa molecule were matching the reported sequence.

CONCLUSIONS

5 This protocol includes concentrating the cell free filtrate using Amberlite XAD-2 batch adsorption chromatography (BAC), acetone fractionation, methacrylate polymer resin BAC and finally through RP-HPLC. Chemical analysis of the purified preparations matched the reported structure for this type of enterotoxin. The biological activity was demonstrated to be less than 0.2 ng per one mouse unit of the STa in 2-3 day-old
10 inoculated Swiss Webster suckling mice. In summary, purification of STa to homogeneity was accomplished and the purity of the produced STa was documented through amino acid sequencing, and mass spectroscopy.

EXAMPLE II.

15

METHODS AND MATERIALS

Reagents. All reagents were obtained from commercial sources and were of analytical grade. Bovine serum albumin (BSA), succinic anhydride (SA), dioxane, *N,N*-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl carbodiimide
20 hydrochloride (EDAC), *N*-methylimidazole, dimethylformamide (DMF), 2-(*N*-morpholino) ethanesulfonic acid buffer (MES), triethylamine (ET₃N), *p*-nitrophenol, sodium azide (NaN₃) and phosphate buffer saline (PBS) tablets were obtained from Sigma Chemical Co. (St. Louis, MO). STa was purified as described in Example I.

*Procedure for covalently cross-linking STa with modified BSA: Chemical
25 modification of bovine serum albumin.* Bovine serum albumin was chemically modified to introduce new carboxyl moieties using two different protocols:

- Succinylation
- Hyper-succinylation

Succinylation of Bovine Serum Albumin

Basis of reaction. Succinic anhydride (SA) reacts rapidly with the E-amino groups of lysines and the α -amino groups of the N-termini of proteins at pH 7-9, forming an amide bond by replacing the amino group with a carboxyl as disclosed in Riordan *et al.* (1964) *Biochemistry* 11, 1768-1774, Gounaris *et al.* (1976) *Journal of Biological Chemistry* 242, 2739-2745 and *The Merck Index*, 12th ed., Merck & Co., Inc. (1996),

(Figure 11). Thus, introducing a succinic anhydride moiety on BSA will afford a protein derivative with more carboxyl groups and hence increase the possibility to link STa from its amino terminal and preserve its antigenic determinants associated with the carboxyl terminal of the molecule.

Procedure: The methods followed were those described by Habeeb (1967) *Biochemistry and Biophysics* 121, 652 and Habeeb (1967) *Journal of Immunology* 99, 1264-1276. Briefly, one gram of BSA was dissolved in 200 ml of 0.2 M borate buffer, pH 9.3. A 20 ml solution of dioxane with 5.4 g succinic anhydride was added in small aliquots over a period 30 minutes, the reaction mixture was stirred magnetically while maintaining the pH at 9.3 through the addition of 3 M NaOH. Following the last addition of succinic anhydride, the acylation reaction was allowed to continue for 45 minutes. The solution was then dialyzed at 4°C against several changes of 0.01 M triethylamine using dialysis tubing with a M.W. cutoff of 12-14 KD. The dialyzed preparation was first freeze-dried and then further dried in a desiccator over phosphorous pentoxide (P₂O₅). Samples were taken and reconstituted in PBS buffer (pH 6.8) for size exclusion chromatography and mass spectroscopy.

Hyper-Succinylated Bovine Serum Albumin (HS-BSA)

Basis of reaction. An extensive modification of the BSA by introducing a large number of succinyl moieties [COO⁻] on the carrier protein could be achieved in the hyper-succinylation reaction. The hyper-succinylation reaction was carried out in two steps. The first step involves the production of hyperaminated BSA by conversion of all free carboxyl groups on the BSA (aspartic and glutamic acids) into amino groups. The second step was the production of hypersuccinylated BSA by addition of succinic anhydride to the hyperaminated BSA to convert all amino groups (newly introduced, free, and N-terminal) into carboxyl groups.

Procedure: Native BSA was treated with 1mM of ethylenediamine at pH 4.75 in the presence of 10 mM EDAC. This hyperaminated protein molecule was then treated with 100 mmoles of succinic anhydride at pH 8.0 for two hours to produce a hyper-succinylated BSA molecule as disclosed in Fuentes *et al.* (2005) *Journal of Immunological Methods* 307, 144-149.

Coupling of E. coli STa to Modified BSA. Four different conjugation protocols were used to covalently cross-linking STa to modified BSA. They were evaluated on the basis of stability of covalent bond, retained STa biological activity and the conjugation efficiency.

Protocol 1: Using Dimethylformamide (DMF) as a solubilizer for the peptide and carrier protein. As described in Atassi (1981) *Biochimica et Biophysica Acta* 670, 300-330, DMF was used to solubilize several synthetic peptides before cross-linking them to carrier proteins. While not limiting the present invention to any particular theory, it is believed that this protocol enhances the coupling of the amino terminal ends of synthetic peptides to the carrier protein. In this study, the carrier protein (suBSA) was solubilized in DMF and then treated with *p*-nitrophenol to activate the carboxyl groups on the carrier.

Procedure: Applying this procedure, we have used the purified native STa peptide and have solubilized it in DMF prior to addition to the modified suBSA. The mixture was kept stirring overnight at room temperature. This design encourages the STa coupling through its amino terminals based on nucleophilic attack at the reactive ester groups of the modified suBSA forming amide linkages. In a typical reaction, 140 mg of suBSA was suspended in 10 ml of anhydrous DMF and stirred it magnetically in a tight-capped foil-wrapped bottle for 3-4 hours. A solution of *p*-nitrophenol (65 mg/0.5 ml) in DMF was added and magnetic stirring continued for 15 minutes. A solution of DCC (50 mg/0.5 ml) was added to suBSA at a molar ratio of 120:1 and the reaction was allowed to continue stirring at room temperature for three hours. 100 mg of STa in 1 ml DMF was added to the activated suBSA at a molar ratio of 24:1. Shortly after, 1 ml of triethylamine was added. The reaction mixture was stirred overnight, at room temperature, while protected from direct light. The next day, 30 ml of Milli Q water was added and the mixture was dialyzed extensively against distilled water at 4°C using a dialysis

membrane with a 12-14 kD M.W. cutoff and then freeze-dried. Samples were taken for measurement of the STa biological activity of the conjugate using suckling mice assay (SMA), protein determination, biochemical and molecular characterization.

Protocol 2: Imidazole-Based Protocol. The coupling procedure disclosed in Dean
5 *et al.* (1990) *Journal of Immunological Methods* 129, 119-125,

may be used to stabilize the carrier protein and minimize the formation of polymers due to the acylation process when the cross linker and the peptides intended for cross-linking are added.

Procedure: 0.5 M *N*-methyl-imidazole, pH 6.0, was used to dissolve the STa
10 peptide and the carrier protein suBSA at a molar ratio (100:1). After the addition of EDAC (molar ratio: 50 mol EDAC/mol STa), the mixture was stirred for 30 minutes at room temperature followed by dialysis (M.W. cutoff: 12-14 kD) against distilled water at 4°C.

Protocol 3: Hyper-Succinylated BSA-Based Protocol. Fuentes *et al.* (2005)
15 *Journal of Immunological Methods* 307, 144-149, reported that an increase in the numbers of succinyl groups [COO⁻] on the carrier protein can enhance the cross linking of the peptides from their amino terminal. The procedure for hyper-succinylation of BSA was previously described herein.

Procedure: In this coupling protocol, 3 mg hypersuccinylated-BSA was dissolved
20 in 2.5 ml of 5 mM sodium phosphate buffer pH 7 and mixed with 2.5 ml of the STa peptide (0.5 mg/ml) in dioxane. EDAC was then added gradually to reach a concentration of 100 mM. After that, the conjugated composite was dialyzed using a tube with a M.W. cutoff 12-14 kD against distilled water at 4°C.

Protocol 4: Conventional Peptide-Carrier Coupling Protocol. In this coupling
25 procedure, suBSA, EDAC and MES buffer were used as disclosed in the EDC Conjugation Protocol Technical Sheet, *Uptima Interchim* (2007).

Procedure: SuBSA carrier protein was dissolved in 0.1 M MES buffer, pH 5, to a
30 final concentration of 10 mg/ml. Two milligrams of STa peptide were added to 2 mg of suBSA carrier protein. Then, EDAC (10 mg/ml in cold distilled water) was added at a ratio of 0.5 mg of EDAC per mg of total protein. The reaction was stirred for 2-3 hours at

room temperature before dialysis at 4°C against PBS using a tube of 12-14 kD molecular weight cutoff.

Dialysis. The products of BSA modification and STa-modified BSA conjugation reactions were subjected to extensive dialysis to remove the small molecular weight reactants (<14 kD). Dialysis tubing with nominal M.W. cut-off 12-14 kD was purchased from Fisher Scientific (Pittsburg, PA). STa-SuBSA conjugate was subjected to extensive dialysis against Milli Q purified water using a dialysis membrane of 12-14 kD M.W. cutoff. Molecular species of 14 kD or higher were retained inside the dialysis tube and all other reactants below 14 kD including uncoupled (free) toxin were dialyzed out.

Gel Filtration Chromatography (GFC). PD-10 columns, Sephadex G-25M packed columns, of a nominal molecular mass exclusion limit of 5000 for protein were purchased from G.E. Healthcare (Buckinghamshire, UK). These columns are designed to separate proteins based on their molecular weight. The columns were equilibrated and developed by following the manufacturer's instructions. The dialyzed STa conjugate samples were passed through PD-IO Sephadex G-25 GFC column to purify the STa-suBSA conjugates from free STa, then assessed for biological activity and protein concentration. A freeze-dried STa-suBSA conjugate sample was reconstituted into 2.5 ml of PBS and passed through a PD-IO column to separate the unconjugated STa peptide from the portion that was successfully cross linked to the carrier protein. The STa-carrier conjugate was then eluted with 3.5 ml PBS and the effluent was collected and tested for biological activity in a suckling mouse assay.

Size-Exclusion High Performance Liquid Chromatography. SE-HPLC was performed to compare the molecular size of both native and modified BSA. Bio-Sil® SEC-125 HPLC 300 x 7.8 mm filtration column (Catalog Number 125-0060) was purchased from BioRad (Hercules, CA) and hooked to the Waters Associate Liquid Chromatography System equipped with multi-solvent delivery pumps, an automated gradient programmer 600S controller and a tunable absorbance detector (Model 486). The column was equilibrated with 0.05 M sodium phosphate (dibasic), 0.05 M sodium phosphate (monobasic), 0.15 M NaCl and 0.01 M NaN₃ at pH 6.8. Isocratic elution system was applied at flow rate of 1 ml/min. The peak absorbance was monitored at UV wavelength of 280 nm.

Amino Acid Compositional Analysis. To determine the conjugation ratio of STa to the modified BSA, a freeze-dried STa-suBSA conjugate sample was subjected to amino acid compositional analysis (Research Technology Support Facility (RTSF), Michigan State University).

5 *Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectroscopy (MALDI-TOF/MS).* 200 micrograms of freeze-dried STa-suBSA conjugate sample were subjected to MALDI-TOF/MS analysis at the MSU-RTSF laboratory to determine precisely the molecular weight of the conjugate and use this figure to calculate the number of STa molecules that covalently cross-linked to one BSA molecule (conjugation
10 ratio).

Protein Assay. Protein assays were performed according to the Lowery method as described in Lowry *et al.* (1951) *Journal of Biological Chemistry* 193, 265-275, using a Perkin Elmer Lambda 3A UV/US spectrophotometer.

15 *STa-suBSA Conjugates Activity Bioassay.* The biological activity of the STa-suBSA conjugates was determined using the suckling mouse assay as described in Saeed *et al.* (1983) *Infection and Immunity* 40, 701.

RESULTS

20 Table VIII shows the summary of conjugation experiments and their evaluation. More details on the DMF conjugation protocol are presented below.

Characteristics of the Modified BSA. The results from SE-HPLC showed that modified BSA with succinic anhydride was eluted faster (RT= 2.99 min) than native BSA (RT= 4.20 min), suggesting that the molecular weight of suBSA had undergone a
25 significance change (Figure 12). Change in the molecular weight of the succinylated BSA was also confirmed by MALDI-TOF/MS. It was found that suBSA has a M.W. of 72.40 kD in comparison to native BSA which has a M.W. of ~67.00 kD (Figure 13).

Characteristics of E. coli STa-suBSA Conjugates. Dialysis and Gel Filtration Chromatography. A summary of the results is presented in Table VIII. The conjugation
30 protocol based on the DMF method showed a higher rate of conjugation efficiency and higher level of retained STa biological activity compared to other conjugates (Table

VIII). Further characterization of the DMF-based conjugation protocol is described below.

Amino Acid Compositional Analysis. A dialyzed conjugate sample based on the DMF protocol was subjected to amino acid compositional analysis. Table IX shows the picomolar concentration and retention time of each amino acid residue.

Calculation of STa Peptide to SuBSA Ratio. The conjugation ratio is defined as the number of STa molecules covalently cross-linked to one molecule of succinylated BSA. The amino acid composition of the conjugate was empirically determined by measuring the picomoles of each amino acid detected in a known volume of sample.

Well-recovered residues, arginine and methionine, were used to quantify the concentration of each residue (pmole) in the conjugate sample. The number of STa molecules in the conjugate sample was calculated using the Arg and Meth residues not present within the sequence of the STa peptide. Table X gives the approximate number of coupled STa molecules to one molecule of modified BSA. Based on the data of amino acid compositional analysis, it was found that approximately 4-5 STa molecules were coupled to each molecule of suBSA.

STa Conjugate Analysis by MALDI-TOF/MS. Lyophilized conjugate samples based on DMF and HS-BSA protocols were subjected to MALDI-TOF/MS to accurately determine the molecular weight (M_r Value). Both samples showed median M_r Values over 80 kDa (Figure 14 and Figure 15). Figure 16 shows the molecular weight differences for the modified BSA before and after STa peptide conjugation ($\Delta M.W. = 8342.5$ Da). This difference was attributed to the contribution of the STa molecules. Based on this data, the median number of STa molecules successfully cross linked to one molecule of suBSA was calculated from the following equation: $\Delta M.W. / STa M.W. = 8342.5/1959 = 4-5$. Four to five STa molecules were successfully cross linked to one molecule of modified BSA based on DMF and HS-BSA protocols.

STa Conjugate Activity Bioassay and Conjugation Efficiency. We concluded that the STa biological activity and the conjugation efficiency of the conjugate were highest in the DMF protocol. A summary of conjugation efficiency based on the tested protocols expressed largely by the conjugation ratios and the retained STa biological activities of the conjugates is presented in Table VIII.

DISCUSSION

Numerous attempts have been made to render STa immunogenic, including chemical coupling and genetic fusions to appropriate carrier proteins as disclosed in
5 Clements (1990) *Infection and Immunity* 58, 1159-1166.

However, results of these studies showed limited success since the uncontrolled cross-linking process led to the loss of the biological activity of STa as a part of the conjugation process as disclosed in Pereira *et al.* (2001) *Microbiology* 147, 861-867. Additionally, these studies showed no sufficient details on the efficiency and
10 the characteristics of the produced STa conjugates. The objective of this study was to design and characterize a well-defined, stable and active STa conjugate for further study of its immunogenicity in laboratory animal models. We have evaluated several conjugation protocols to achieve a stable biologically active STa conjugate through carefully planned cross-linking of the STa peptide to a modified carrier protein using
15 BSA, carbodiimide derivatives and different solvents. Given the perceived molecular structure of the STa peptide and the desire to crosslink it through its amino terminus, we have selected carbodiimide coupling reagents. Other coupling reagents, glutaraldehyde and *m*-Maleimidobenzoyl-*N*-hydroxysuccinimide ester (MBS), may affect the 3-dimensional structure of the STa peptide. Glutaraldehyde binds non-specific amino
20 groups and this leads to polymerization of peptide and/ or carrier protein, which results in a poorly defined conjugate as disclosed in Molin *et al.* (1978) *The Journal of Histochemistry and Cytochemistry* 26, 412-414.

Cysteine residues on the STa peptide play a crucial role in the biological activity and the stability of STa peptide. Thus, using MBS as a hetero-bifunctional reagent targeting thiol
25 group on cysteine residue as disclosed in Carlson *et al.* (1978) *Biochemical Journal* 173, 723 and Yoshitaki *et al.* (1979) *European Journal of Biochemistry* 101, 395,

may disrupt the disulfide bonds and affect the biological moieties on the STa peptide. BSA is widely used as a carrier protein in conjugation reactions because it is highly antigenic and can be easily modified to
30 introduce a new moiety for specific coupling procedures as disclosed in Habeeb (1967) *Biochemistry and Biophysics* 121, 652 and Habeeb (1967) *Journal of Immunology* 99,

1264-1276. Therefore, the use of carbodiimide and BSA, in our conjugation reaction was justified based on a thorough understanding of the molecular structure of the STa peptide. In this study, BSA was modified by introducing succinic moieties, and its modification was confirmed using size exclusion chromatography and MALDI/TOF/MS. The data showed a 5000 Da difference in the molecular size between the modified and native BSA molecules, indicating an 8% increase in the M.W. of the modified BSA. This suggests that an extensive modification of the free amino groups was achieved with the addition of succinic anhydride as disclosed in Habeeb (1967) *Journal of Immunology* 99, 1264-1276. The subsequent step in the design of STa-BSA conjugate was the cross-linking of STa to the modified BSA. This reaction was initiated by incubation of the modified BSA with p-nitrophenol and DCC for three hours to provide reactive ester groups that could easily attach the STa from its amino terminal, forming amide linkages. The use of DMF was shown to enhance the solubility of reactants including peptides and carrier proteins as disclosed in Lateef (2007) *Journal of Biomolecular Techniques* 18, 173-176.

We believe that the use of DMF as a solvent reagent may have facilitated the solubility of the hydrophobic STa molecules, solving a problem encountered with the other solvents and coupling media. The STa-conjugate was tested for its protein content and biological activity. Based on the protein estimation, there was a conjugation efficiency of 52-64%, which is higher than previously disclosed in Frantz *et al.* (1981) *Infection and Immunity* 33, 193-198; Frantz *et al.* (1987) *Infection and Immunity* 55, 1077-1084 and Thompson *et al.* (1990) *Journal of Receptor Research* 10, 97-117.

Moreover, this conjugate showed a higher biological activity than any activity reported in the previous STa-conjugates (Table VIII). Based on these results, it is clear that most of the biological activity of the STa introduced into this reaction was retained in the conjugate even after extensive dialysis, GFC and SEC. Covalent attachment of STa molecules to modified BSA was documented by amino acid composition analysis and MALDI-TOF/MS. A median value for the conjugation ratio of 4-5:1 STa:suBSA has been determined based on amino acid analysis and MALDI-TOF/MS (Figure 16). Based on the results of the biological activity of this conjugate, we believe strongly that STa molecules may have been more efficiently oriented on the BSA carrier molecule via linkage through their

amino terminals. Such orientation, achieved through the DMF protocol, has preserved the biologically active moiety of the STa and may offer an explanation for the relatively low yield of STa conjugate produced by other protocols in this study. The ineffective preservation and presentation of the STa biologically active moiety on previously studied

5 STa conjugates may also explain the sub-optimal immune response against STa in laboratory animals (Alderete *et al.* (1978) *Infection and Immunity* 19, 1021-1030; Lockwood *et al.* (1984) *Journal of Immunological Methods* 75, 295-307; Löwenadler *et al.* (1991) *FEMS Microbiology Letters* 82, 271-278 and Pereira *et al.* (2001) *Microbiology* 147, 861-867.

10 In summary, we have designed a well-defined STa-conjugate based on a thorough understanding of the molecular structure of the STa peptide. After careful evaluation of several peptide-carrier conjugation protocols, we have defined the conditions for a conjugate that expressed a high STa biological activity in suckling mice. Its stability and biochemical attributes were characterized using GFC, amino acid analysis and MALDI-

15 TOF/mass spectroscopy.

EXAMPLE III.

METHODS AND MATERIALS

20 *Reagents and instruments.* STa-suBSA conjugates were designed and characterized as described in the previous chapter. All buffers ingredients, Freund's complete and incomplete adjuvant, alkaline phosphatase labeled goat-anti-rabbit IgG antibodies, p-nitrophenyl phosphate, fish gelatin, Tween-20 and ammonium thiocyanate (NH₄SCN) were obtained from Sigma Chemical (St. Louis, MO). Costar 3590 96-well

25 microtiter plates were obtained from Fisher Scientific (Fairlawn, NJ). Molecular Devices ThermoMax Microplate reader equipped with SOFT max Pro 2.6.1 was used to read the ELISA plate. A bleeding set (coagulant vacutainer tubes, adaptors and 20 gauge vacutainer needles) was obtained from Becton-Dickinson (BD) (Franklin Lakes, NJ) and used for rabbit bleeding.

30 *Animals.* Ten female New-Zealand albino rabbits (2-4 kg) were obtained from Charles River Laboratories (Wilmington, MA) and were housed in approved-size-single

cages at the Containment Facility of Michigan State University. Temperature was kept at 20°C ± 4°C, with 55% humidity. Rabbits were checked on a daily basis for their health status by qualified staff and veterinarians.

Immunization procedure. Standard operating procedures for handling and immunization of rabbits in compliance with the guidelines and recommendations for the Institutional Animal Care and Use Committee (IACUC) of Michigan State University were used. A water-in-oil emulsion of STa-conjugate in Freund's adjuvant was prepared as follows: 20 mg of freeze-dried STa-suBSA conjugate was reconstituted in 10 ml 0.01 M PBS-pH 7.0 and added to 10 ml of Freund's complete adjuvant (primary immunization). The mixture was homogenized with a polytron at 15,000 rpm for up to 10 minutes or until a stable water-in-oil emulsion was obtained. The ten rabbits were inoculated at multiple intradermal sites as disclosed in Vaitukaitis (1981) *Methods in Enzymology* 73, 46-52, with 0.5 ml of the described emulsion. Each rabbit was similarly inoculated with a booster dose at three-week intervals with 0.5 ml of STa conjugates mixed with Freund's incomplete adjuvant. Rabbits received boosters until STa-neutralizing antibodies titers were detected.

Animal bleeding. Pre-immunization blood samples were collected after one week of adaptation from the central ear artery as provided for in Gordon (1981) *Journal of Immunological Methods* 44, 241-224, using serum separator BD-vacutainer tubes to obtain a reference baseline for serum titers. Blood samples were then collected three weeks after the primary immunization, approximately 4-5 days after each booster immunization. After collection, blood was allowed to clot for 60 min at 37°C. The clot was then separated from the sides of the collection vessel and allowed to contract at 4°C overnight. The separated sera were collected by centrifugation at 2000 rpm for 30 min, aliquoted and kept at -20°C. The sera were tested for neutralization and binding capacity against STa using suckling mouse assay (SMA) and indirect ELISA binding assay respectively.

STa-Serum Neutralization Assay. The STa-serum neutralization capacity was determined using the SMA as described by Frantz *et al.* (1987).

Briefly, three 50 µL aliquots of serum sample with were incubated with 25, 50 and 75 µL of STa (20 mouse units per µL) at 37°C for 2 hours. The contents of each

tube were brought to a final volume of 0.5 ml with PBS, before bioassay. Three mice were used for each sample. In addition, two controls were included; one has the 25 μ L STa mixed with similar volumes of PBS instead of the tested sera and the second control had 25 μ L STa mixed with similar volume of base line serum of the corresponding rabbit.

5 All samples were treated similarly. Neutralization end titer of tested serum is defined as the highest serum dilution that neutralized one mouse unit of STa. Neutralization capacity is defined as the total mouse units of STa that were neutralized per one ml serum. Neutralization specific activity is defined as the total mouse units of STa that were neutralized per one mg serum protein.

10 *Kinetics of the Rabbit Immune Response to ETEC STa Antibody-Capture ELISA for Screening Sera.* An indirect antibody-capture ELISA in which STa antigen was bound to a solid phase and reaction with antibody-containing samples was allowed (Figure 20) in order to monitor the presence of STa antibodies in rabbit sera as described under the ELISA protocol as provided for in Lefkovits (1997) *Immunology Methods Manual*,
 15 Harcourt Brace and Co., San Diego, CA. The ELISA

plates were coated with 2.5 μ g STa and 100 μ L of 0.05 M carbonate buffer, pH 9.6, (plate coating buffer) and incubated overnight at 4°C. Plates were washed four times with 0.01 M PBS-0.05% Tween-20 and blotted dry. 100 μ L of 0.5% cold fish gelatin-0.01% M PBS-0.1% Tween-20 (blocking buffer) was added to each well to block nonspecific
 20 binding sites on the plastic surface and incubated at 37°C for 30 minutes. Plates were then washed with 0.01 M PBS-0.1% Tween-20 (washing buffer) and blotted. Serum samples collected from all rabbits over the period of immunization were screened at a ten-fold dilution with PBS-0.1% Tween-20. 100 μ L of each serum dilution (10^{-3} , 10^{-4} , 10^{-5} and 10^{-6}) was added to each well, in triplicate, and incubated at 37°C for 45 minutes.

25 After four washings and blotting, 100 μ L of 1000-fold diluted alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies (1 μ L/ml) was added to each well, incubated at 37°C for 45 minutes. Plates were washed as previously described and 100 μ L of freshly prepared substrate solution (one tablet set of *p*-nitrophenyl phosphate (*p*NPP/PBS)/5ml in 0.1 M diethanolamine buffer, pH 9.8) was added to each well. The reaction was allowed
 30 to develop for 30 minutes at 37°C. The developed color was read at 405 nm with an ELISA plate reader (Molecular Devices "ThermoMax" Microplate Reader with SOFT

Max Pro 2.6.1). Reciprocal value of the maximal dilution of serum that had a mean plus 2 standard deviations ($\bar{x} + 2 SO$) O.D. value or higher than the O.D. of the baseline serum sample, was reported as antibody end titer for each tested serum sample.

Avidity ELISA. Avidity (Functional Affinity) is the measure of the overall strength of interaction of an antigen with many antigenic determinants with multivalent antibodies as provided for in Goldblatt (2001) *Encyclopedia of Life Sciences*, John Wiley and Sons, New York.

In this study, the STa-antibody avidity was measured by comparing the amount of antibodies that could bind the STa antigen in the presence or absence of increasing concentrations of a chaotropic agent. In this test, a mild chaotropic agent, ammonium thiocyanate" was added in increasing molar concentrations to the antibody-antigen mixture. Antibodies of low avidity are more likely to dissociate from antigen-antibody complexes than those of higher avidity as described by Ferreira *et al.* (1995) *Journal of Immunological Methods* 187, 297-305.

The procedure was performed using similar steps to the ELISA protocol described above. However, after the final incubation of the tested sera, four washings and blotting, 100 μ L of three different molar concentrations of ammonium thiocyanate in PBS (5 M, 2.5 M, and 1.25 M) were added to each well, in duplicates, incubated at 37°C for 15 minutes. Plates were processed then as described under the ELISA protocol. Avidity index was calculated as a percentage of the O.D. of the sample with different concentrations of ammonium thiocyanate and the O.D. of the sample without treatment. Serum samples obtained from rabbits before the initial immunization were used as baseline controls.

Statistical analysis. Generated ELISA O.D. data were adjusted and subjected to statistical analysis for the calculation of the mean and standard deviation. ELISA O.D. data was plotted using Microsoft Excel.

RESULTS

Characterization of Serum Antibody Response in STa-Conjugate-Immunized Rabbits. Sera from immunized rabbits were tested for STa-serum neutralization capacity as described under the methods section. Tested sera from three rabbits showed a positive

neutralization capacity in suckling mouse assay (gut weight to body weight ratio = 0.06 ± 0.001) (Figure 18) and up to 3×10^4 mouse units of STa could be completely neutralized by one ml of serum (Figure 19). Neutralizing antibodies were first detected among these rabbits after 12 weeks post-immunization (fourth immunization). These three rabbits were grouped retrospectively as "group 1" based on the onset of the detectable neutralizing ST-antibody titers. At week 17, post-immunization, another three rabbits had a detectable neutralization titer. These rabbits were grouped as "group 2". At week twenty-four, two more rabbits had mild neutralization capacity against *E. coli* STa. These rabbits were grouped as "group 3". Figure 20 shows *E. coli* STa-specific serum antibody neutralization bioassay from all rabbits.

Binding activity. Indirect ELISA was used to determine the binding capacity of anti-STa IgG. Figures 21 through 29 shows the results of binding data for sera from seven bleedings of all rabbits that were giving antibodies against STa at various serum dilutions (10^{-3} to 10^{-6}). The 10^{-4} dilution was recognized as the optimal dilution for screening the tested sera for STa-binding capacity (Figure 21), the equivalence point of antigen antibody interaction).

Three weeks after the primary immunization, detectable neutralizing IgG antibodies against STa were not observed. However, based on ELISA assay, slight binding titers were detected. Higher binding antibody titers were only detected 12 weeks post-immunization (Figure 22). Other three rabbits showed late immune response at week 17 post-immunization (Figure 23), however higher antibody binding titers (10^6) and STa-neutralizing antibodies (3×10^4 MU/ml serum) were then detected. By 24 weeks post-immunization, other two rabbits mounted mild neutralization and binding titer against *E. coli* STa (Figure 24). Figures 25-29 shows the end titer of *E. coli* STa-specific serum antibody. Mean OD \pm SD values of STa-specific serum antibody end titer of groups 1, 2 and 3 rabbits after 24-week post-immunization at various serum dilutions are shown in Table XI. Summary of STa-ELISA binding and neutralization end titers of rabbit sera immunized with STasu-BSA conjugate after the primary immunization and during the boosting intervals are presented in Table XII.

STa- binding avidity of the rabbit immune sera. The dissociation effect of ammonium thiocyanate on the STa-binding to its specific antibodies was demonstrated.

The dissociation effect of the chaotropic agent on the STa-antibody binding using sera from a rabbit with the highest neutralizing antibody titer is shown in Figure 30. Sera from other rabbits demonstrated similar avidity patterns. The figure shows the time course evaluation of STa-IgG avidity using ammonium thiocyanate dose response. The increasing molar concentration of ammonium thiocyanate (1.25 M-5 M) needed to dissociate STa-IgG complex is depicted suggesting that the strength of the STa-IgG avidity developed gradually after multiple boosters with the STa-conjugate. A 5 M concentration of the chaotropic agent was determined to be the appropriate cutoff point in order to demonstrate the strength of the avidity of STa-specific serum antibodies. Mean values of the ODs of serum ELISA for the three groups of rabbits assayed using 5 M of the ammonium thiocyanate are depicted in Figure 31 and summarized in Table XIII. It is noted that there is some variation in the patterns of dissociation of the STa-antibodies from sera of the 3 groups of rabbits, which are largely corresponding to the STa-neutralization and binding titers established for these sera. The avidity index which is calculated by dividing the OD of the sera in the binding ELISA with 5 M of chaotropic agent by the OD of the ELISA binding result for the same sera without treatment with the chaotropic agent (Figure 32 & Table XIII). By week 24, post-immunization, sera from all three groups of rabbits demonstrated variable avidity indices. It was noted that sera from the first group of rabbits had the highest avidity index, which is associated with the high STa-neutralization and binding titers demonstrated for these sera.

DISCUSSION

Construction of immunogenic ETEC STa has been reported by several investigators who used different chemical coupling protocols to link the STa to carrier proteins as well as the genetic expression of the STa with flagellin as a fusion protein as disclosed in Houghten *et al.* (1984) *European Journal of Biochemistry* 145, 157-162; Sanchez *et al.* (1988) *FEBS Letters* 208, 194-198; Clements (1990) *Infection and Immunity* 58, 1159-1166; Klipstein *et al.* (1983) *The Journal of Infectious Diseases* 147, 318-326; and Pereira *et al.* (2001) *Microbiology* 147, 861-867.

However, limited success in producing high titers STa antisera was reported in those studies. This could be attributed to the uncontrolled cross-linking

process of the STa to the carrier proteins which led to the reduction or loss of the STa biological activity as a part of the conjugate as disclosed in Pereira *et al.* (2001) *Microbiology* 147, 861-867. An important objective of this study was to design and characterize an effective immunogenic STa conjugate using the major different peptide-carrier conjugation protocols. Based on the evaluation of four different conjugation procedures, a well-defined STa conjugate with high STa biological activity was produced.

Immunization of ten rabbits with this STa-conjugate led to the production of STa-specific neutralizing antibodies by eight animals. The STa-neutralization and specific binding titers of these sera were higher than those disclosed in Alderete *et al.* (1978) *Infection and Immunity* 19, 1021-1030; Frantz *et al.* (1981) *Infection and Immunity* 55, 1077-1084; Lockwood *et al.* (1984) *Journal of Immunological Methods* 75, 295-307; Löwenadler *et al.* (1991) *FEMS Microbiology Letters* 82, 271-278; and Pereira *et al.* (2001) *Microbiology* 147, 861-867.

However, some variations in the onset and quality of the immune responses were noticed. Two rabbits demonstrated weaker STa neutralizing titer 20 weeks post-immunization. It is not fully understood why some rabbits differed in their immune response to the STa immunogen. Such individual variations may warrant additional investigation in future studies. Comparing data on the STa binding and STa neutralization titers of the sera produced in this study with data from previous reports is presented in Table XIV. Measurement of the avidity of the STa-antibodies using a chaotropic agent, ammonium thiocyanate at several increasing molar concentrations suggested that the avidity of the STa neutralizing antibodies improved throughout the series of boosters administered to the rabbits. Comparison of the avidity of the serum antibodies demonstrated that the strength in the STa antibody avidity developed in time corresponding to the development of the STa-neutralizing and ELISA binding titers of the tested sera. This is consistent with the common knowledge about maturation of antibodies after immunization and continuous boosting protocols as disclosed in Goldblatt, *Encyclopedia of Life Sciences*, John Wiley and Sons, New York (2001). In summary,

we have described the design of a highly defined STa-conjugate and its use in the induction of high STa neutralization and ELISA binding serum titers in immunized

rabbits. The carefully designed STa-conjugate and the produced high STa-neutralizing serum antibodies can be evaluated for the design of effective vaccine and/or immunotherapeutic reagents against the STa-producing *E. coli* strains that are associated with a significant proportion of diarrheal disease worldwide.

5

EXAMPLE IV.

METHODS AND MATERIALS

Reagents and instruments. STa-suBSA conjugates were designed and characterized as described in the previous chapter. All buffers ingredients, Freund's complete and incomplete adjuvant, alkaline phosphatase labeled goat-anti-rabbit IgG antibodies, p-nitrophenyl phosphate, fish gelatin, Tween-20 and ammonium thiocyanate (NH₄SCN) were obtained from Sigma Chemical (St. Louis, MO). Costar 3590 96-well microtiter plates were obtained from Fisher Scientific (Fairlawn, NJ). Molecular Devices ThermoMax Microplate reader equipped with SOFT max Pro 2.6.1 was used to read the ELISA plate. A bleeding set (coagulant vacutainer tubes, adaptors and 20 gauge vacutainer needles) was obtained from Becton-Dickinson (BD) (Franklin Lakes, NJ) and used for rabbit bleeding.

Animals. Twenty four White leghorn chickens (160 -day-old hens) were kept in Michigan State University containment facility for the duration of immunization. Eggs were collected from each bird before primary immunization for baseline.

Immunization procedure. Standard operating procedures for handling and immunization of chickens in compliance with the guidelines and recommendations for the Institutional Animal Care and Use Committee (IACUC) of Michigan State University were used. Primary immunization was performed following the subcutaneous route at the neck fold. Each bird received 0.25mg conjugate protein emulsified in CFA. Immunizations were repeated on days 14 and 28 using Incomplete Freund's adjuvant. Eggs were collected twice /week from each bird. Weekly pools of eggs were processed for IgY extraction from each bird during the immunization protocol for determination of neutralization capacity of the IgY to STa using suckling mouse assay.

30

STa neutralization bioassay. Neutralization activity will be assayed according to Frantz et al., (1987) by incubating dilutions of mammalian antibody (IgG), egg yolk antibody (IgY) and PBS (control) with 25 effective doses (10ng) of STa at 37 °C for 2 hr in a final volume 100 µl. The contents of each tube were diluted with PBS to 1.0 ml before bioassay. Neutralization titer was expressed as an extrapolated value for the last dilution of IgY that reduce fluid accumulation from the positive control, generally with a gut weight to bodyweight ratio of 0.110 to 0.083. Figure 33 shows a flow chart for the standardization and optimization of the process of egg yolk antibodies extraction and purification.

10 RESULTS

Confirmation for the purity and specificity of the produced IGY was demonstrated by: Figure 34, in which Size Exclusion Chromatography (SEC) of extracted IgY vs standard chromatogram of SEC molecular weight standards are shown. Figure 35 shows the Dose Response Competitive ELISA to establish specificity of the purified IgY from hens before immunization as a baseline. Figure 36 shows the kinetics of egg yolk-derived STa-neutralizing antibody. Data shows the mean and standard deviation from yolk extract of 6 birds followed over 30 week period after primary immunization followed by boosters. Horizontal red line indicates the cut off for effective STa-neutralization is a gut wt/remaining body wt ratio of 0.083 (Y axis). Table XV shows the neutralization capacity of STa-specific IgY extracted from egg yolk samples of 24 hens immunized with the STa vaccine. STa neutralization scores based on suckling mouse assay. A ratio of gut weight: remaining body weight of < 0.085 signifies a positive STa - neutralization. Avidity index (%) for each sample is listed in the last column. Figure 37 shows the kinetics of immune response and levels of STa-neutralization measured by suckling mouse assay (Y axis) in 24 hens immunized with the STa vaccine and sampled over 30 weeks period.

CONCLUSION

The use of the ETEC STa vaccine, recently developed by Dr. A. Mahdi Saeed of Michigan State University and described under the provisional patent application, for the

immunization of egg laying hens resulted in the production of a STa-neutralizing immune response. The ST-a specific antibody levels could be measured after extraction of the antibodies from the yolk of eggs laid by the immunized hens.

5 The production and demonstration of an effective Immunoglobulin Y (IgY) with neutralizing capacity to the ETEC STa opens a wide window for prophylactic and therapeutic use of the antibody against ETEC STa-caused diarrheal disease in human and animals. The following is a summary of the proposed embodiments of the produced reagent invention:

A. Prophylactic use:

10 1. The egg yolk-derived antibody can be enterically coated and administered in appropriate doses to susceptible subjects (infants, adult travelers during the time of highest susceptibility) to offer protection against the STa-diarrhea.

15 2. This reagent can be commercialized as an additive to infant formula milk in endemic areas to offer protection to infants who are very susceptible to diarrheal disease.

3. The reagent can be similarly added as an additive to milk replacers that are given to new borne calves and piglets to offer protection against calf and piglet scour that is known to have a significant toll on the health and survival of young animals.

20 B. Therapeutic use: The antibody can also be used immunotherapeutically to treat subjects (humans and animals) suffering from STa-diarrhea. These subjects include human infants and adults and newly borne animals. Of particular importance is the possibility of alleviating the severity of diarrheal disease in subjects that are severely affected such as infants, the elderly, and the immunocompromized subjects.

TABLE I

Properties	STa = STI	STb = STII
Size	<2kDa	5.1 kDa
Number of amino acid residues	18-19 amino acids	48 amino acids
Mechanism of synthesis and secretion	Pre-pro form 72 amino-acid precursor followed by two consecutive peptidase cleavages before extracellular diffusion of 18-19 amino acid mature toxin	71 amino-acid precursor processed into 48 amino acid mature toxin secreted extracellularly without further processing
Number of cysteine residues	Six cysteine residues Three S-S bonds	Four cysteine residues Two S-S bonds
Toxic domain	Hydrophobic; 11-14 amino acid especially Ala 13	Charged amino acids: especially lys-22, lys 23, arg 29 and asp-30
Solubility	Methanol soluble	Methanol insoluble
Activity	Active in mice, infant, piglet and calves	Inactive in suckling mice but active in rats and ligated piglet intestinal segment. Have no effect on human small intestine.
Trypsin effect	Resistant	Sensitive
Mechanism of action	Act on guanylyl cyclase C	Does not act on cyclic nucleotides. Ca, PGE2 and serotonin may be its mode of action
Effect on enterocytes:	No effect	Loss of villus epithelial cells and partial villus atrophy (Nagy and Fekete 1999)
Prototypes	STaP (porcine isolates) and STaH (human isolate)	None
Producing strains	ETEC and other bacteria	Only ETEC

TABLE II

Toxin and host	No. Amino acids	Sequence	Reference
STaH ETEC	19	N-S-S-N-Y-C-C-E-L-C-C-N-P-A-C-T-G-C-Y (SEQ ID NO: 13)	Aimoto et al 1982
STaP ETEC	18	N-T-F-Y-C-C-E-L-C-C-N-P-A-C-A-G-C-Y (SEQ ID NO: 12)	Takan et al 1983
STa ETEC (bovine)	18	N-T-F-Y-C-C-E-L-C-C-N-P-A-C-A-G-C-Y (SEQ ID NO: 11)	Saeed et al 1984
<i>Citrobacter Freundii</i>	18	N-T-F-Y-C-C-E-L-C-C-N-P-A-C-A-G-C-Y (SEQ ID NO: 10)	Guarino et al 1989
<i>Yersinia enterocolitica</i>	30	S-S-D-Y-D-C-C-D-Y-C-C-N-P-A-C-A-G-C (SEQ ID NO: 9)	Takao et al 1985
<i>V. cholera Non-O1</i>	17	I-D-C-C-E-I-C-C-N-P-A-C-F-G-C-L-N (SEQ ID NO: 19)	Yoshimura et al 1986
<i>V. cholera non- O1 Hatake</i>	18	L-I-D-C-C-E-I-C-C-N-P-A-C-F-G-C-L-N (SEQ ID NO: 18)	Arita et al 1991
<i>V. mimicus</i>	17	I-D-C-C-E-I-C-C-N-P-A-C-F-G-C-L-N (SEQ ID NO: 17)	Arita et al 1991
<i>E. coli EAST-1</i>	38	...A-S-S-Y-A-S-C-I-W-C-T--T-A-C-A-S-C-H-G (SEQ ID NO: 16)	Savarino et al 1993
<i>Comus geographus 13</i>	13	E-C-C-N-P-A-C-G-R-H-Y-S-C (SEQ ID NO: 15)	Gray et al 1981
Guanylin (human)	15	P--G-T-C-E-I-C-C-A-Y-A-A-C-T-G-C (SEQ ID NO: 14)	Greenberg et al 1997

TABLE III

	Primer	Sequence (5-3)	Base pair	Reference
(SEQ ID NO: 1) (SEQ ID NO: 2)	STa	5'- TCC GTG AAA CAA CAT GAC GG-3' 5'- ATA ACA TCC AGC ACA GGC AG-3'	244	Salvadori et al. 2003
(SEQ ID NO: 3) (SEQ ID NO: 4)	ST1	5'-TTA ATA GCA CCC GGT ACA AGC AGG-3' 5'-CTT GAC TCT TCA AAA GAG AAA ATT AC-3'	127	Olsvick, and Strockbine 1993

TABLE IV

Step	Temperature (°C)	Time (min)
Pre-denature	95	5
Denature	95	1
Annealing	60	1
Extension	72	1
Final extension	72	10
Storage	4	24 hours

Number of PCR cycles 29 before storage

TABLE V

Component	Amount/sample (μ l)	# of Samples	Amount/two rxns Volume (μ l)
10x buffer A	2	2.5	5
dNTP (10mM)	0.4	2.5	1
Sta-F (20 μ M)	0.4	2.5	1
Sta-R (20 μ M)	0.4	2.5	1
25 mM MgCl ₂	0	0	0
Fisher Taq polymerase	0.1	2.5	1
Ultrapure water	14.7	2.5	36.75
Total volume	20		45
Template	2		

TABLE VI

NaCl	2.52	Na ₂ SO ₄	0.14
Na acetate	10.00	MgSO ₄	0.05
K ₂ HPO ₄ ·3H ₂ O	8.12	MnCl ₂ 1%	0.5 ml
Asparagine	5.00	FeCl ₃ 1%	0.5 ml

TABLE VII

Step	Volume ml	Titer	Total MU/ 10 ⁷	Protein Conc /mg	Sp Ac MU x 10 ³ /mg	MED ng	Purification fold
Cell Free Filtrate	30 x 10 ³	10 ⁻²	3	24,660	1.22	822	1
Amberlite XAD-2 BAC	120	10 ⁻⁴	1.2	1,378	8.70	114.9	7.13
Acetone Fractionation	60	10 ⁻⁵	6	676.8	88.7	11.28	72.67
60%MCI-gel F	30	10 ⁻⁵	3	267.6	112.10	8.92	91.88
RP-HPLC	80	10 ⁻⁶	80	90.4	8849.56	0.113	7253.28

TABLE VIII

	SuBSA/DMF Method	HSBSA/PB Method	SuBSA/Imidazole Method	Conventional Method
Carrier	suBSA	HS-BSA	suBSA	SuBSA
Cross linker	Organic soluble carbodiimide (DCC)	Water soluble carbodiimide (EDAC)	Water soluble carbodiimide (EDAC)	Water soluble carbodiimide (EDAC)
Medium	N,N, DMF	5 mM PB (Na ₂ HPO ₄ /NaH ₂ PO ₄)	Imidazole	0.1 M MES
pH	7-9	7	7.2	5
Starting reactants	10 mg STa + 14 mg suBSA + 6.5 mg p-NP	5 mg STa + 12 mg HS-BSA	10 mg STa + 3.3 mg suBSA	2 mg STa + 2 mg suBSA
Total STa MU	10 x 10 ⁶	48x10 ⁴	4x10 ⁶	3x10 ²
Protein Assay	1.96mg/ml	0.277mg/ml	1.8mg/ml	1.2mg/ml
Conjugation ratio	4-5:1	4:1	-	-
Conjugation efficiency (Lowery protein)	~52-64%	~ 26%	~ 40.6%	~30%
Conjugation efficiency (retained biological activity)	100%	~20%	40%	30%
Reference	Atassi et al 1981	Fuentes et al 2005	Dean et al. 1990	Ujima, 2007

TABLE IX

Serial #	Name	RT	Amount pmole	Serial #	Name	RT	Amount pmole
1	Gln	1.78	5.983	10	Tyr	37.09	499.248
2	Glu	20.63	549.781	11	Cys	37.53	509.796
3	Ser	25.61	147.557	12	Val	37.85	297.137
4	Gly	27.42	329.482	13	Meth	39.214	38.214
5	His	29.29	174.214	14	Ile	43.65	118.619
6	Thr	30.47	311.339	15	Leu	44.80	576.721
7	Arg	31.57	219.833	16	Lys	46.87	333.965
8	Ala	31.886	507.974	17	Phe	38.22	386.2
9	Pro	33.18	377.778	18			

TABLE X

Residue	Total # of residue in STn-suBSA conjugate sample	# of residue /one BSA molecule	# of residue /one STa molecule	Conjugation Ratio
Threonine	$311.339/8.00 = 38.9$	34 residues	1	$38.9-34 = 4.5$
Cysteine	$509.796/8.00 = 63.6$	35 residues	6	$63.6-35 = 28.6/6 = 4.5$
Leucine	$576.721/8.00 = 72$	65 residues	1	$72-65 = 7$
Alanine	$507.974/8.00 = 63.5$	48 residues	2	$63.5-48 = 15.5/2 = 7.8$

TABLE XI

Group/serum dilution	10^{-3}	10^{-4}	10^{-5}	10^{-6}
G1	1.933 ± 0.013	1.923 ± 0.014	1.237 ± 0.568	0.379 ± 0.352
G2	1.964 ± 0.035	1.969 ± 0.031	1.550 ± 0.010	0.374 ± 0.173
G3	1.936 ± 0.006	1.656 ± 0.035	0.354 ± 0.015	0.040 ± 0.010
Baseline	0.864 ± 0.318	0.232 ± 0.155	0.033 ± 0.048	0.039 ± 0.060

TABLE XII

Bleeding	Anti-STa Response		Protein Assay mg/ml	Neutralization Specific Activity
	ELISA Titer	Neutralized STa MU/ml serum (Titer)		
Baseline	0	0	64.5	-
Week 3 PI	0	0	66.8	-
Week 6 PI	0	0	65.7	-
Week 12 PI	10,000	2000	83.5	23.95
Week 15 PI	100,000	15,000	69.6	215.52
Week 20 PI	1,000,000	20,000	65.00	307.69
Week 24 PI	1,000,000	20,000	65.00	307.69
Week 28 PI	1,000,000	30,000	65.00	461.54

TABLE XIII

	Baseline	Week 3	Week 6	Week 12/17	Week 24
	Avidity Index (AI) % after measurement OD at 405 nm				
Group 1	0.017 (4.70%)	0.043 (8.91%)	0.001 (0.03%)	0.578 (25.94%)	0.927 (48.21%)
Group 2	0.043 (3%)	0 (0%)	0.022 (2.24%)	0.027 (1.53%)	0.762 (38.71%)
Group 3	0.04 (0%)	0 (0%)	0.095 (11.36%)	0.151 (12.05%)	0.352 (21.30%)

TABLE XIV

References	Maximum neutralization titer	Amount of SMU	Neutralization capacity Total MU/ml serum
Löwenadler et al. 1991	1:55	30	1665
Lockwood and Robertson 1984	1:100	8	800
Frantz and Robertson 1981	1:5000 to 1:10,000	1	5000 to 10,000
Alderete and Robertson 1978	1:2,500	1	2,500
Pereira et al. 2001	1:50 for immunogene using native STa fusion protein	1	50
	1:4000 using mutated STa fusion protein	1	4,000
<i>This study</i>	1:30,000	1	30,000

TABLE XV

Bird. No.	STa neutralization	Neutralization Score	Avidity
	G.weight/remaining B. Weight		Index (%)
1	0.073	++	76.44
2	0.078	+	66.70
3	0.056	++++	91.24
4	0.065	+++	85.58
5	0.066	+++	79.59
6	0.064	+++	52.79
7	0.061	+++	96.46
8	0.068	+++	93.60
9	0.055	+++	59.60
10	0.073	++	82.28
11	0.073	++	54.72
12	0.072	++	86.16
13	0.066	+++	106.17
14	0.066	+++	48.74
15	0.076	++	87.35
16	0.063	+++	76.83
17	0.070	+++	69.35
18	0.067	+++	88.23
19	0.077	++	71.59
20	0.082	+	80.42
21	0.073	++	74.89
22	0.083	-/+	70.72
23	0.085	-/+	85.34
24	0.081	+	69.84

What is claimed is:

1. A vaccine comprising a heat-stable enterotoxin protein from *Escherichia coli* comprising an amino terminus, a cross-linker comprising first and second ends, and a carrier protein, wherein said first end of said cross-linker is covalently attached to said amino terminus of said enterotoxin and said second end of said cross-linker is covalently attached to said carrier protein via a carrier protein succinylated group that is a succinylated lysine group or a succinylated N-terminal amino group.
2. A vaccine comprising an immunogenic conjugate that comprises heat-stable enterotoxin (STa) protein from *Escherichia coli* comprising an amino terminus that is covalently attached to a carrier protein via a carrier protein succinylated group that is a succinylated lysine group or a succinylated N-terminal amino group, wherein the vaccine conjugation efficiency is at least 52% and/or the retained biological activity is 100%.
3. The vaccine of claim 1 or 2, wherein said carrier protein is keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin (OVA), beta-galactosidase (B-GAL), penicillinase, poly-DL-alanyl-poly-L-lysine, or poly-L-lysine.
4. The vaccine of claim 1 or 2, wherein said carrier protein is bovine serum albumin.
5. The vaccine of claim 4, wherein the ratio of enterotoxin molecules to one molecule of bovine serum albumin is between 1 and 10.
6. The vaccine of any one of claims 1 to 5, wherein said vaccine generates antibody having a specific binding titer of at least 10^{-6} .
7. The vaccine of any one of claims 1 to 6, wherein said enterotoxin protein has a specific activity of at least 1.22×10^3 Mouse Unit per milligram (MU/mg).

8. The vaccine of any one of claims 1 to 6, wherein said enterotoxin protein has a specific activity of at least 8.70×10^3 MU/mg.
9. The vaccine of any one of claims 1 to 6, wherein said enterotoxin protein has a specific activity of at least 885×10^4 MU/mg.
10. The vaccine of any one of claims 1 to 9, wherein said vaccine generates antibody having a neutralization capacity of at least 3×10^4 STa mouse units/ml.
11. The vaccine of any one of claims 1 to 10 for treating a subject at risk for diarrhea or a diarrheal related disease or disorder.
12. The vaccine of claim 11, wherein the subject is pregnant with an unborn mammal.
13. The vaccine of claim 11 or 12 for generating an immune response to enterotoxin, wherein the immune response comprises antibodies in the colostrum of said subject.
14. Use of the vaccine of any one of claims 1 to 10 for the prevention of diarrhea or a diarrheal related disease or disorder in a subject.
15. Use of the vaccine of any one of claims 1 to 10 in preparation of a medicament for the prevention of diarrhea or a diarrheal related disease or disorder in a subject.
16. The use of claim 14 or 15, wherein the vaccine is for one or more of prophylactic administration, parenteral administration, transdermal administration, intradermal administration, intramuscular administration, intraperitoneal administration, intravenous administration, subcutaneous administration, epidural administration, mucosal administration, intranasal administration, rectal administration, vaginal administration, sublingual administration, buccal administration, and oral administration.

17. The use of claim 14 or 15, wherein the vaccine is for prophylactic administration.
18. The use of any one of claims 14 to 17, wherein said diarrhea or diarrheal related disease or disorder is selected from the group consisting of secretory diarrhea, osmotic diarrhea, motility-related diarrhea, inflammatory diarrhea, dysentery, infectious diarrhea, malabsorption disorders, inflammatory bowel syndrome, ischemic bowel disease, bowel cancer, hormone-secreting tumor related disorders, bile-salt diarrhea and chronic ethanol ingestion.
19. The use of any one of claims 14 to 18, wherein said subject is a mammal.
20. The use of claim 19, wherein the subject is pregnant.
21. The use of any one of claims 14 to 20, wherein the vaccine is for generating an immune response to enterotoxin, wherein said immune response results in antibodies in the colostrum of the subject.
22. A vaccine comprising an immunogenic conjugate that consists of heat-stable enterotoxin (STa) protein from *Escherichia coli* that is covalently attached to a succinylated carrier protein, wherein the vaccine conjugation efficiency is at least 52% and/or the retained biological activity is 100%.
23. The vaccine of claim 22, wherein said carrier protein is bovine serum albumin.
24. The vaccine of claim 23, wherein the ratio of enterotoxin molecules to one molecule of bovine serum albumin is between 1 and 10.
25. The vaccine of claim 22, 23, or 24, wherein said enterotoxin protein has a specific activity of at least 1.22×10^3 Mouse Unit per milligram (MU/mg).

26. The vaccine of claim 22, 23, or 24, wherein said enterotoxin protein has a specific activity of at least 8.70×10^3 MU/mg.
27. The vaccine of claim 22, 23, or 24, wherein said enterotoxin protein has a specific activity of at least 885×10^4 MU/mg.
28. The vaccine of any one of claims 22 to 27, wherein said vaccine generates antibody having a neutralization capacity of at least 3×10^4 STa mouse units/ml.
29. The vaccine of any one of claims 22 to 28, wherein said vaccine generates an antibody having a specific binding titer of at least 10^{-6} .

FIGURE 1




FIGURE 2






FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32




FIGURE 33




FIGURE 34





FIGURE 35

IgY MW = ~ 180 kD



Retention Time (min)	Area	Height	Width	Resolution
10.0	1000	100	1.0	1.0
15.0	1500	150	1.0	1.0
20.0	2000	200	1.0	1.0
25.0	2500	250	1.0	1.0
30.0	3000	300	1.0	1.0
35.0	3500	350	1.0	1.0
40.0	4000	400	1.0	1.0
45.0	4500	450	1.0	1.0
50.0	5000	500	1.0	1.0
55.0	5500	550	1.0	1.0
60.0	6000	600	1.0	1.0
65.0	6500	650	1.0	1.0
70.0	7000	700	1.0	1.0
75.0	7500	750	1.0	1.0
80.0	8000	800	1.0	1.0
85.0	8500	850	1.0	1.0
90.0	9000	900	1.0	1.0
95.0	9500	950	1.0	1.0
100.0	10000	1000	1.0	1.0
105.0	10500	1050	1.0	1.0
110.0	11000	1100	1.0	1.0
115.0	11500	1150	1.0	1.0
120.0	12000	1200	1.0	1.0
125.0	12500	1250	1.0	1.0
130.0	13000	1300	1.0	1.0
135.0	13500	1350	1.0	1.0
140.0	14000	1400	1.0	1.0
145.0	14500	1450	1.0	1.0
150.0	15000	1500	1.0	1.0
155.0	15500	1550	1.0	1.0
160.0	16000	1600	1.0	1.0
165.0	16500	1650	1.0	1.0
170.0	17000	1700	1.0	1.0
175.0	17500	1750	1.0	1.0
180.0	180000	18000	1.0	1.0
185.0	18500	1850	1.0	1.0
190.0	19000	1900	1.0	1.0
195.0	19500	1950	1.0	1.0
200.0	20000	2000	1.0	1.0
205.0	20500	2050	1.0	1.0
210.0	21000	2100	1.0	1.0
215.0	21500	2150	1.0	1.0
220.0	22000	2200	1.0	1.0
225.0	22500	2250	1.0	1.0
230.0	23000	2300	1.0	1.0
235.0	23500	2350	1.0	1.0
240.0	24000	2400	1.0	1.0
245.0	24500	2450	1.0	1.0
250.0	25000	2500	1.0	1.0
255.0	25500	2550	1.0	1.0
260.0	26000	2600	1.0	1.0
265.0	26500	2650	1.0	1.0
270.0	27000	2700	1.0	1.0
275.0	27500	2750	1.0	1.0
280.0	28000	2800	1.0	1.0
285.0	28500	2850	1.0	1.0
290.0	29000	2900	1.0	1.0
295.0	29500	2950	1.0	1.0
300.0	30000	3000	1.0	1.0
305.0	30500	3050	1.0	1.0
310.0	31000	3100	1.0	1.0
315.0	31500	3150	1.0	1.0
320.0	32000	3200	1.0	1.0
325.0	32500	3250	1.0	1.0
330.0	33000	3300	1.0	1.0
335.0	33500	3350	1.0	1.0
340.0	34000	3400	1.0	1.0
345.0	34500	3450	1.0	1.0
350.0	35000	3500	1.0	1.0
355.0	35500	3550	1.0	1.0
360.0	36000	3600	1.0	1.0
365.0	36500	3650	1.0	1.0
370.0	37000	3700	1.0	1.0
375.0	37500	3750	1.0	1.0
380.0	38000	3800	1.0	1.0
385.0	38500	3850	1.0	1.0
390.0	39000	3900	1.0	1.0
395.0	39500	3950	1.0	1.0
400.0	40000	4000	1.0	1.0
405.0	40500	4050	1.0	1.0
410.0	41000	4100	1.0	1.0
415.0	41500	4150	1.0	1.0
420.0	42000	4200	1.0	1.0
425.0	42500	4250	1.0	1.0
430.0	43000	4300	1.0	1.0
435.0	43500	4350	1.0	1.0
440.0	44000	4400	1.0	1.0
445.0	44500	4450	1.0	1.0
450.0	45000	4500	1.0	1.0
455.0	45500	4550	1.0	1.0
460.0	46000	4600	1.0	1.0
465.0	46500	4650	1.0	1.0
470.0	47000	4700	1.0	1.0
475.0	47500	4750	1.0	1.0
480.0	48000	4800	1.0	1.0
485.0	48500	4850	1.0	1.0
490.0	49000	4900	1.0	1.0
495.0	49500	4950	1.0	1.0
500.0	50000	5000	1.0	1.0

FIGURE 36




FIGURE 37

